{"id":3331,"date":"2021-12-17T14:21:50","date_gmt":"2021-12-17T06:21:50","guid":{"rendered":"https:\/\/neuroaid.com\/estudios-clinicos\/"},"modified":"2025-07-22T10:12:25","modified_gmt":"2025-07-22T02:12:25","slug":"estudios-clinicos","status":"publish","type":"page","link":"https:\/\/neuroaid.com\/es\/estudios-clinicos\/","title":{"rendered":"Estudios cl\u00ednicos"},"content":{"rendered":"[vc_row type=\u00bbfull_width_background\u00bb full_screen_row_position=\u00bbmiddle\u00bb column_margin=\u00bbdefault\u00bb column_direction=\u00bbdefault\u00bb column_direction_tablet=\u00bbdefault\u00bb column_direction_phone=\u00bbdefault\u00bb bg_color=\u00bb#ffffff\u00bb scene_position=\u00bbcenter\u00bb top_padding=\u00bb0&#8243; text_color=\u00bbdark\u00bb text_align=\u00bbleft\u00bb row_border_radius=\u00bbnone\u00bb row_border_radius_applies=\u00bbbg\u00bb overflow=\u00bbvisible\u00bb overlay_strength=\u00bb0.3&#8243; gradient_direction=\u00bbleft_to_right\u00bb shape_divider_position=\u00bbbottom\u00bb bg_image_animation=\u00bbnone\u00bb shape_type=\u00bb\u00bb][vc_column column_padding=\u00bbno-extra-padding\u00bb column_padding_tablet=\u00bbinherit\u00bb column_padding_phone=\u00bbinherit\u00bb column_padding_position=\u00bball\u00bb column_element_direction_desktop=\u00bbdefault\u00bb column_element_spacing=\u00bbdefault\u00bb desktop_text_alignment=\u00bbdefault\u00bb tablet_text_alignment=\u00bbdefault\u00bb phone_text_alignment=\u00bbdefault\u00bb background_color_opacity=\u00bb1&#8243; background_hover_color_opacity=\u00bb1&#8243; column_backdrop_filter=\u00bbnone\u00bb column_shadow=\u00bbnone\u00bb column_border_radius=\u00bbnone\u00bb column_link_target=\u00bb_self\u00bb column_position=\u00bbdefault\u00bb gradient_direction=\u00bbleft_to_right\u00bb overlay_strength=\u00bb0.3&#8243; width=\u00bb1\/1&#8243; tablet_width_inherit=\u00bbdefault\u00bb animation_type=\u00bbdefault\u00bb bg_image_animation=\u00bbnone\u00bb border_type=\u00bbsimple\u00bb column_border_width=\u00bbnone\u00bb column_border_style=\u00bbsolid\u00bb]\n\t\t\t<!-- START Clinical studies v6 REVOLUTION SLIDER 6.7.35 --><p class=\"rs-p-wp-fix\"><\/p>\n\t\t\t<rs-module-wrap id=\"rev_slider_216_1_wrapper\" data-source=\"gallery\" style=\"visibility:hidden;background:transparent;padding:0;margin:0px auto;margin-top:0;margin-bottom:0;\">\n\t\t\t\t<rs-module id=\"rev_slider_216_1\" style=\"\" data-version=\"6.7.35\">\n\t\t\t\t\t<rs-slides style=\"overflow: hidden; position: absolute;\">\n\t\t\t\t\t\t<rs-slide style=\"position: absolute;\" data-key=\"rs-444\" data-title=\"africa\" data-anim=\"adpr:false;\" data-in=\"o:0;\" data-out=\"a:false;\">\n\t\t\t\t\t\t\t<img decoding=\"async\" src=\"\/\/neuroaid.com\/wp-content\/plugins\/revslider\/sr6\/assets\/assets\/dummy.png\" alt=\"\" title=\"doctor-patient-DWZ4F2W-min\" width=\"2560\" height=\"1350\" class=\"rev-slidebg tp-rs-img rs-lazyload\" data-lazyload=\"\/\/neuroaid.com\/v2\/wp-content\/uploads\/doctor-patient-DWZ4F2W-min-scaled-e1621913717530.jpg\" data-parallax=\"4\" data-no-retina>\n<!--\n\t\t\t\t\t\t\t--><rs-group\n\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-16\" \n\t\t\t\t\t\t\t\tdata-type=\"group\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"xo:-128px,-103px,-43px,-29px;yo:126px,95px,96px,88px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,16,12,7;l:0,20,15,9;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:482,391,297,183;h:324px,263px,199px,122px;\"\n\t\t\t\t\t\t\t\tdata-triggercache=\"keep\"\n\t\t\t\t\t\t\t\tdata-frame_0=\"o:1;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"st:a;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:a;sR:8700;sA:9000;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:27;\"\n\t\t\t\t\t\t\t><!--\n\t\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-28\" \n\t\t\t\t\t\t\t\t\tdata-type=\"image\"\n\t\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\t\tdata-xy=\"x:c,l,l,l;xo:1016px,884px,664px,384px;y:m,t,t,t;yo:30px,94px,78px,160px;\"\n\t\t\t\t\t\t\t\t\tdata-pos=\"a\"\n\t\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,16,12,7;l:0,20,15,9;\"\n\t\t\t\t\t\t\t\t\tdata-dim=\"w:303px,238px,155.99px,106.98599999999999px;h:202px,158.986px,104px,71px;\"\n\t\t\t\t\t\t\t\t\tdata-basealign=\"group\"\n\t\t\t\t\t\t\t\t\tdata-frame_1=\"e:power4.inOut;st:480;sp:1500;sR:480;\"\n\t\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;sR:7020;\"\n\t\t\t\t\t\t\t\t\tstyle=\"z-index:26;\"\n\t\t\t\t\t\t\t\t><img decoding=\"async\" src=\"\/\/neuroaid.com\/wp-content\/plugins\/revslider\/sr6\/assets\/assets\/dummy.png\" alt=\"\" class=\"tp-rs-img rs-lazyload\" width=\"1000\" height=\"667\" data-lazyload=\"\/\/neuroaid.com\/v2\/wp-content\/uploads\/NAII_3-e1613530758649.png\" data-no-retina title=\"\"> \n\t\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-26\" \n\t\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\t\tdata-color=\"rgba(25, 56, 138, 0.8)\"\n\t\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\t\tdata-xy=\"x:c;xo:-21px,-21px,-50px,-14px;y:m;yo:-98px,-83px,-58px,-29px;\"\n\t\t\t\t\t\t\t\t\tdata-pos=\"a\"\n\t\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,15,14;l:58,47,35,24;ls:5,3px,2px,3px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-256;||o:click;a:stoplayer;layer:slider-216-slide-444-layer-21;ch:false;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;||o:click;a:togglelayer;ls:hidden;layer:slider-216-slide-444-layer-19;ch:true;'\n\t\t\t\t\t\t\t\t\tdata-basealign=\"group\"\n\t\t\t\t\t\t\t\t\tdata-frame_1=\"e:power4.inOut;sp:1500;\"\n\t\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sp:1000;sR:8000;auto:true;\"\n\t\t\t\t\t\t\t\t\tstyle=\"z-index:25;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t\t>Acerca \n\t\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-27\" \n\t\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\t\tdata-color=\"#3d3d3d\"\n\t\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\t\tdata-xy=\"x:c;xo:124px,103px,45px,43px;y:m;yo:33px,5px,8px,51px;\"\n\t\t\t\t\t\t\t\t\tdata-pos=\"a\"\n\t\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,16,12,13;l:30,24,18,16;\"\n\t\t\t\t\t\t\t\t\tdata-dim=\"w:406.993px,331.99px,251px,183.997px;\"\n\t\t\t\t\t\t\t\t\tdata-basealign=\"group\"\n\t\t\t\t\t\t\t\t\tdata-frame_1=\"e:power4.inOut;sp:1500;\"\n\t\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;sR:7500;\"\n\t\t\t\t\t\t\t\t\tstyle=\"z-index:24;font-family:'Arial', 'Helvetica', 'sans-serif';\"\n\t\t\t\t\t\t\t\t>NeuroAiD es un tratamiento oral que ayuda a los pacientes de accidentes cerebrovasculares y lesiones cerebrales traum\u00e1ticas que sufren d\u00e9ficits establecidos a recuperar su independencia funcional adem\u00e1s de terapias de rehabilitaci\u00f3n y ejercicios. \n\t\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-25\" \n\t\t\t\t\t\t\t\t\tdata-type=\"shape\"\n\t\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\t\tdata-xy=\"xo:-693px,-646px,-858px,-1280px;\"\n\t\t\t\t\t\t\t\t\tdata-pos=\"a\"\n\t\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,16,12,7;l:0,20,15,9;\"\n\t\t\t\t\t\t\t\t\tdata-dim=\"w:1299px,1138px,1206.97px,1520.993px;h:1509.97px,1226px,931px,574px;\"\n\t\t\t\t\t\t\t\t\tdata-basealign=\"group\"\n\t\t\t\t\t\t\t\t\tdata-frame_1=\"e:power4.inOut;sp:1500;\"\n\t\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;sR:7500;\"\n\t\t\t\t\t\t\t\t\tstyle=\"z-index:23;background-color:#f4f4f4;\"\n\t\t\t\t\t\t\t\t> \n\t\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-24\" \n\t\t\t\t\t\t\t\t\tdata-type=\"shape\"\n\t\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\t\tdata-xy=\"xo:1128px,875px,655px,234px;yo:87px,75px,62px,38px;\"\n\t\t\t\t\t\t\t\t\tdata-pos=\"a\"\n\t\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,16,12,7;l:0,20,15,9;\"\n\t\t\t\t\t\t\t\t\tdata-dim=\"w:3px,3px,2px,1px;h:220px,200px,147px,90px;\"\n\t\t\t\t\t\t\t\t\tdata-basealign=\"group\"\n\t\t\t\t\t\t\t\t\tdata-frame_1=\"e:power4.inOut;st:880;sp:1500;sR:880;\"\n\t\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;sR:6620;\"\n\t\t\t\t\t\t\t\t\tstyle=\"z-index:22;background-color:#f4f4f4;\"\n\t\t\t\t\t\t\t\t> \n\t\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t\t--><a\n\t\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-7\" \n\t\t\t\t\t\t\t\t\tclass=\"rs-layer\"\n\t\t\t\t\t\t\t\t\thref=\"https:\/\/neuroaid.com\/es\/acerca-de-neuroaid\/\" target=\"_self\"\n\t\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\t\tdata-color=\"rgba(255, 255, 255, 0.8)\"\n\t\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\t\tdata-xy=\"x:c;xo:575px,453px,323px,256px;y:m;yo:-60px,-45px,-29px,-4px;\"\n\t\t\t\t\t\t\t\t\tdata-pos=\"a\"\n\t\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,15,14;l:58,47,35,24;ls:5,3px,2px,2px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-252;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;'\n\t\t\t\t\t\t\t\t\tdata-basealign=\"group\"\n\t\t\t\t\t\t\t\t\tdata-frame_0=\"sX:0.9;sY:0.9;\"\n\t\t\t\t\t\t\t\t\tdata-frame_1=\"st:250;sp:1000;sR:250;\"\n\t\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sp:1000;sR:7750;auto:true;\"\n\t\t\t\t\t\t\t\t\tdata-frame_hover=\"sX:1.2;sY:1.2;c:#fff;e:default;\"\n\t\t\t\t\t\t\t\t\tstyle=\"z-index:21;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t\t>Acerca de NeuroAiD \u25b8 \n\t\t\t\t\t\t\t\t<\/a><!--\n\n\t\t\t\t\t\t\t\t--><a\n\t\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-10\" \n\t\t\t\t\t\t\t\t\tclass=\"rs-layer\"\n\t\t\t\t\t\t\t\t\thref=\"https:\/\/neuroaid.com\/es\/perfil-de-seguridad\/\" target=\"_self\"\n\t\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\t\tdata-color=\"rgba(255, 255, 255, 0.8)\"\n\t\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\t\tdata-xy=\"x:c;xo:573px,445px,319px,252px;y:m;yo:121px,89px,78px,82px;\"\n\t\t\t\t\t\t\t\t\tdata-pos=\"a\"\n\t\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,15,14;l:58,47,35,24;ls:5,3px,2px,2px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-254;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;'\n\t\t\t\t\t\t\t\t\tdata-basealign=\"group\"\n\t\t\t\t\t\t\t\t\tdata-frame_0=\"sX:0.9;sY:0.9;\"\n\t\t\t\t\t\t\t\t\tdata-frame_1=\"st:250;sp:1000;sR:250;\"\n\t\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sp:1000;sR:7750;auto:true;\"\n\t\t\t\t\t\t\t\t\tdata-frame_hover=\"sX:1.2;sY:1.2;c:#fff;e:default;\"\n\t\t\t\t\t\t\t\t\tstyle=\"z-index:20;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t\t>perfil de seguridad \u25b8 \n\t\t\t\t\t\t\t\t<\/a><!--\n\n\t\t\t\t\t\t\t\t--><a\n\t\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-12\" \n\t\t\t\t\t\t\t\t\tclass=\"rs-layer\"\n\t\t\t\t\t\t\t\t\thref=\"https:\/\/neuroaid.com\/es\/composicion-y-dosis\/\" target=\"_self\"\n\t\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\t\tdata-color=\"rgba(255, 255, 255, 0.8)\"\n\t\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\t\tdata-xy=\"x:c;xo:634px,489px,353px,286px;y:m;yo:-2px,-1px,4px,25px;\"\n\t\t\t\t\t\t\t\t\tdata-pos=\"a\"\n\t\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,15,14;l:58,47,35,24;ls:5,3px,2px,2px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\t\tdata-dim=\"w:auto,auto,auto,235.997px;\"\n\t\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-255;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;'\n\t\t\t\t\t\t\t\t\tdata-basealign=\"group\"\n\t\t\t\t\t\t\t\t\tdata-frame_0=\"sX:0.9;sY:0.9;\"\n\t\t\t\t\t\t\t\t\tdata-frame_1=\"st:250;sp:1000;sR:250;\"\n\t\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sp:1000;sR:7750;auto:true;\"\n\t\t\t\t\t\t\t\t\tdata-frame_hover=\"sX:1.2;sY:1.2;c:#fff;e:default;\"\n\t\t\t\t\t\t\t\t\tstyle=\"z-index:19;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t\t>composici\u00f3n y dosificaci\u00f3n \u25b8 \n\t\t\t\t\t\t\t\t<\/a><!--\n\n\t\t\t\t\t\t\t\t--><a\n\t\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-9\" \n\t\t\t\t\t\t\t\t\tclass=\"rs-layer\"\n\t\t\t\t\t\t\t\t\thref=\"https:\/\/neuroaid.com\/es\/estudios-clinicos\/\" target=\"_self\"\n\t\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\t\tdata-color=\"rgba(255, 255, 255, 0.8)\"\n\t\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\t\tdata-xy=\"x:c;xo:556px,455px,327px,260px;y:m;yo:58px,45px,40px,53px;\"\n\t\t\t\t\t\t\t\t\tdata-pos=\"a\"\n\t\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,15,14;l:58,47,35,24;ls:5,3px,2px,2px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-253;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;'\n\t\t\t\t\t\t\t\t\tdata-basealign=\"group\"\n\t\t\t\t\t\t\t\t\tdata-frame_0=\"sX:0.9;sY:0.9;\"\n\t\t\t\t\t\t\t\t\tdata-frame_1=\"st:250;sp:1000;sR:250;\"\n\t\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sp:1000;sR:7750;auto:true;\"\n\t\t\t\t\t\t\t\t\tdata-frame_hover=\"sX:1.2;sY:1.2;c:#fff;e:default;\"\n\t\t\t\t\t\t\t\t\tstyle=\"z-index:18;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t\t>estudios cl\u00ednicos \u25b8 \n\t\t\t\t\t\t\t\t<\/a><!--\n\n\t\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-17\" \n\t\t\t\t\t\t\t\t\tdata-type=\"shape\"\n\t\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\t\tdata-xy=\"x:c;\"\n\t\t\t\t\t\t\t\t\tdata-pos=\"a\"\n\t\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,16,12,7;l:0,20,15,9;\"\n\t\t\t\t\t\t\t\t\tdata-dim=\"w:4492.99px,3650px,3242.99px,3123.99px;h:844.99px,685px,520px,320px;\"\n\t\t\t\t\t\t\t\t\tdata-basealign=\"group\"\n\t\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;sR:8700;\"\n\t\t\t\t\t\t\t\t\tstyle=\"z-index:17;background-color:#19388a;\"\n\t\t\t\t\t\t\t\t> \n\t\t\t\t\t\t\t\t<\/rs-layer><!--\n\t\t\t\t\t\t\t--><\/rs-group><!--\n\n\t\t\t\t\t\t\t--><a\n\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-1\" \n\t\t\t\t\t\t\t\tclass=\"rs-layer\"\n\t\t\t\t\t\t\t\thref=\"https:\/\/neuroaid.com\/es\" target=\"_self\"\n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-color=\"rgba(255, 255, 255, 0.8)\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:c,l,l,l;xo:-563px,24px,124px,35px;y:m;yo:-178px,-147px,-137px,-128px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,18,14;l:58,58,58,24;ls:5px,3px,2px,2px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\tdata-vbility=\"t,t,f,f\"\n\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-353;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;'\n\t\t\t\t\t\t\t\tdata-frame_0=\"sX:0.9;sY:0.9;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"st:250;sp:1000;sR:250;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sR:7750;auto:true;\"\n\t\t\t\t\t\t\t\tdata-frame_hover=\"sX:1.2;sY:1.2;c:#1e1e1e;e:default;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:14;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t>Inicio \n\t\t\t\t\t\t\t<\/a><!--\n\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-2\" \n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-color=\"rgba(255, 255, 255, 0.8)\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:c,l,l,l;xo:-406px,117px,170px,74px;y:m;yo:-178px,-148px,-100px,-98px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,18,14;l:58,47,35,24;ls:5px,3px,2px,2px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\tdata-vbility=\"t,t,f,f\"\n\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-251;||o:click;a:stoplayer;layer:slider-216-slide-444-layer-21;ch:false;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;||o:click;a:togglelayer;ls:hidden;layer:slider-216-slide-444-layer-16;ch:true;'\n\t\t\t\t\t\t\t\tdata-frame_0=\"sX:0.9;sY:0.9;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"st:250;sp:1000;sR:250;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sp:1000;sR:7750;auto:true;\"\n\t\t\t\t\t\t\t\tdata-frame_hover=\"sX:1.2;sY:1.2;c:#1e1e1e;e:default;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:11;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t>Acerca \u25be \n\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t--><a\n\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-3\" \n\t\t\t\t\t\t\t\tclass=\"rs-layer\"\n\t\t\t\t\t\t\t\thref=\"https:\/\/neuroaid.com\/es\/biblioteca\/\" target=\"_self\"\n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-color=\"rgba(255, 255, 255, 0.8)\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:c;xo:205px,154px,0,0;y:m;yo:-178px,-148px,-100px,-98px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,18,14;l:58,47,35,24;ls:5px,3px,2px,2px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\tdata-vbility=\"t,t,f,f\"\n\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-256;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;'\n\t\t\t\t\t\t\t\tdata-frame_0=\"sX:0.9;sY:0.9;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"st:250;sp:1000;sR:250;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sp:1000;sR:7750;auto:true;\"\n\t\t\t\t\t\t\t\tdata-frame_hover=\"sX:1.2;sY:1.2;c:#1e1e1e;e:default;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:12;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t>Biblioteca \n\t\t\t\t\t\t\t<\/a><!--\n\n\t\t\t\t\t\t\t--><a\n\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-4\" \n\t\t\t\t\t\t\t\tclass=\"rs-layer\"\n\t\t\t\t\t\t\t\thref=\"https:\/\/neuroaid.com\/es\/contacto\/\" target=\"_self\"\n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-color=\"rgba(255, 255, 255, 0.8)\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:c;xo:398px,319px,256px,178px;y:m;yo:-178px,-148px,-137px,-128px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,18,14;l:58,47,35,24;ls:5px,3px,2px,2px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\tdata-vbility=\"t,t,f,f\"\n\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-256;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;'\n\t\t\t\t\t\t\t\tdata-frame_0=\"sX:0.9;sY:0.9;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"st:250;sp:1000;sR:250;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sp:1000;sR:7750;auto:true;\"\n\t\t\t\t\t\t\t\tdata-frame_hover=\"sX:1.2;sY:1.2;c:#1e1e1e;e:default;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:15;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t>contacto \n\t\t\t\t\t\t\t<\/a><!--\n\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-5\" \n\t\t\t\t\t\t\t\tdata-type=\"shape\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:c;xo:0,-6px,-4px,-2px;y:m;yo:-12px,-19px,-14px,-8px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,16,12,7;l:0,20,15,9;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:8003,6504,4941,3048;h:4806,3905,2966,1829;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"e:power4.inOut;sp:1500;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;sR:7500;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:8;background-color:rgba(61,61,61,0.36);\"\n\t\t\t\t\t\t\t> \n\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t--><a\n\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-6\" \n\t\t\t\t\t\t\t\tclass=\"rs-layer\"\n\t\t\t\t\t\t\t\thref=\"https:\/\/buy.neuroaid.com\/es\" target=\"_self\"\n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-color=\"rgba(255, 255, 255, 0.8)\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:c;xo:557px,443px,172px,119px;y:m;yo:-178px,-148px,-100px,-98px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,18,14;l:58,47,35,24;ls:5px,3px,2px,2px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\tdata-vbility=\"t,t,f,f\"\n\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-256;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;'\n\t\t\t\t\t\t\t\tdata-frame_0=\"sX:0.9;sY:0.9;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"st:250;sp:1000;sR:250;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sp:1000;sR:7750;auto:true;\"\n\t\t\t\t\t\t\t\tdata-frame_hover=\"sX:1.2;sY:1.2;c:#1e1e1e;e:default;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:16;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t>pedido \n\t\t\t\t\t\t\t<\/a><!--\n\n\t\t\t\t\t\t\t--><a\n\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-11\" \n\t\t\t\t\t\t\t\tclass=\"rs-layer\"\n\t\t\t\t\t\t\t\thref=\"https:\/\/neuroaid.com\/es\/profesionales-medicos\/\" target=\"_self\"\n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-color=\"rgba(255, 255, 255, 0.8)\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:c,l,c,c;xo:-115px,246px,0,-11px;y:m;yo:-178px,-148px,-137px,-128px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,18,18,14;l:25,25,25,24;ls:5px,3px,2px,2px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\tdata-vbility=\"t,t,f,f\"\n\t\t\t\t\t\t\t\tdata-actions='o:click;a:jumptoslide;slide:rs-353;||o:click;a:toggleclass;layer:slider-216-slide-444-layer-5;class:open;'\n\t\t\t\t\t\t\t\tdata-frame_0=\"sX:0.9;sY:0.9;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"st:250;sp:1000;sR:250;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"st:w;sR:7750;auto:true;\"\n\t\t\t\t\t\t\t\tdata-frame_hover=\"sX:1.2;sY:1.2;c:#1e1e1e;e:default;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:13;font-family:'Arial', 'Helvetica', 'sans-serif';text-transform:uppercase;cursor:pointer;\"\n\t\t\t\t\t\t\t>Profesional m\u00e9dico<br \/>\n \n\t\t\t\t\t\t\t<\/a><!--\n\n\t\t\t\t\t\t\t--><a\n\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-18\" \n\t\t\t\t\t\t\t\tclass=\"rs-layer rev-btn\"\n\t\t\t\t\t\t\t\thref=\"https:\/\/neuroaid.com\/es\/consulta\/\" target=\"_self\"\n\t\t\t\t\t\t\t\tdata-type=\"button\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:c;y:b;yo:131px,98px,106px,90px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:14,14,12,15;l:60,60,50,28;ls:3px,3px,2px,1px;fw:900;a:center;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:auto,auto,auto,450px;minh:0,none,none,none;\"\n\t\t\t\t\t\t\t\tdata-basealign=\"slide\"\n\t\t\t\t\t\t\t\tdata-padding=\"t:0,0,0,10;r:36,36,30,17;b:0,0,0,10;l:36,36,30,17;\"\n\t\t\t\t\t\t\t\tdata-border=\"bos:solid;boc:rgba(255, 255, 255, 0.5);bow:2px,2px,2px,2px;\"\n\t\t\t\t\t\t\t\tdata-frame_0=\"x:0,0,0px,0px;y:0,0,0px,0px;\"\n\t\t\t\t\t\t\t\tdata-frame_1=\"x:0,0,0px,0px;y:0,0,0px,0px;e:power2.out;sp:500;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;e:power2.in;st:w;sp:500;sR:8500;\"\n\t\t\t\t\t\t\t\tdata-frame_hover=\"bgc:rgba(30,30,30,0.76);gs:sliding;boc:transparent;bor:0px,0px,0px,0px;bos:solid;bow:2px,2px,2px,2px;e:power1.inOut;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:9;background-color:rgba(0,0,0,0);font-family:'Roboto';text-transform:uppercase;\"\n\t\t\t\t\t\t\t>Descubra si Neuroaid es adecuado para usted \n\t\t\t\t\t\t\t<\/a><!--\n\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-216-slide-444-layer-38\" \n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-color=\"#fff\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"x:c;yo:189px,153px,116px,115px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:70,56,42,40;l:90,73,55,45;fw:700;a:left,left,left,center;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:auto,auto,auto,400px;minh:0px,none,none,none;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;sR:8700;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:10;font-family:'Arial', 'Helvetica', 'sans-serif';\"\n\t\t\t\t\t\t\t>Estudios Cl\u00ednicos \n\t\t\t\t\t\t\t<\/rs-layer><!--\n-->\t\t\t\t\t<\/rs-slide>\n\t\t\t\t\t<\/rs-slides>\n\t\t\t\t\t<rs-static-layers><!--\n\t\t\t\t\t--><\/rs-static-layers>\n\t\t\t\t<\/rs-module>\n\t\t\t\t<script>\n\t\t\t\t\tsetREVStartSize({c: 'rev_slider_216_1',rl:[1240,1023,778,480],el:[500,400,340,330],gw:[1260,1024,778,480],gh:[500,400,340,330],type:'standard',justify:'',layout:'fullwidth',mh:\"0\"});if (window.RS_MODULES!==undefined && window.RS_MODULES.modules!==undefined && window.RS_MODULES.modules[\"revslider2161\"]!==undefined) {window.RS_MODULES.modules[\"revslider2161\"].once = false;window.revapi216 = undefined;if (window.RS_MODULES.checkMinimal!==undefined) window.RS_MODULES.checkMinimal()}\n\t\t\t\t<\/script>\n\t\t\t<\/rs-module-wrap>\n\t\t\t<!-- END REVOLUTION SLIDER -->\n[\/vc_column][\/vc_row][vc_row type=\u00bbin_container\u00bb full_screen_row_position=\u00bbmiddle\u00bb column_margin=\u00bbdefault\u00bb column_direction=\u00bbdefault\u00bb column_direction_tablet=\u00bbdefault\u00bb column_direction_phone=\u00bbdefault\u00bb scene_position=\u00bbcenter\u00bb top_padding=\u00bb50&#8243; text_color=\u00bbdark\u00bb text_align=\u00bbleft\u00bb row_border_radius=\u00bbnone\u00bb row_border_radius_applies=\u00bbbg\u00bb overflow=\u00bbvisible\u00bb overlay_strength=\u00bb0.3&#8243; gradient_direction=\u00bbleft_to_right\u00bb enable_shape_divider=\u00bbtrue\u00bb shape_divider_color=\u00bb#f4f4f4&#8243; shape_divider_position=\u00bbtop\u00bb shape_divider_height=\u00bb400&#8243; bg_image_animation=\u00bbnone\u00bb shape_type=\u00bbfan\u00bb][vc_column column_padding=\u00bbno-extra-padding\u00bb column_padding_tablet=\u00bbinherit\u00bb column_padding_phone=\u00bbinherit\u00bb column_padding_position=\u00bball\u00bb column_element_direction_desktop=\u00bbdefault\u00bb column_element_spacing=\u00bbdefault\u00bb desktop_text_alignment=\u00bbdefault\u00bb tablet_text_alignment=\u00bbdefault\u00bb phone_text_alignment=\u00bbdefault\u00bb background_color_opacity=\u00bb1&#8243; background_hover_color_opacity=\u00bb1&#8243; column_backdrop_filter=\u00bbnone\u00bb column_shadow=\u00bbnone\u00bb column_border_radius=\u00bbnone\u00bb column_link_target=\u00bb_self\u00bb column_position=\u00bbdefault\u00bb gradient_direction=\u00bbleft_to_right\u00bb overlay_strength=\u00bb0.3&#8243; width=\u00bb1\/1&#8243; tablet_width_inherit=\u00bbdefault\u00bb animation_type=\u00bbdefault\u00bb bg_image_animation=\u00bbnone\u00bb border_type=\u00bbsimple\u00bb column_border_width=\u00bbnone\u00bb column_border_style=\u00bbsolid\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1749699901268{padding-top: 0px !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Invertimos continuamente en la investigaci\u00f3n sobre NeuroAiD; los hallazgos se publican regularmente en revistas especializadas y se presentan en congresos internacionales.<\/h4>\n<p>&nbsp;<\/p>\n<h4><\/h4>\n<h4>Nuestro equipo ha colaborado con expertos de renombre mundial en m\u00e1s de 20 centros de investigaci\u00f3n y contin\u00faa forjando alianzas acad\u00e9micas para seguir explorando sus propiedades y beneficios prometedores para nuevas indicaciones en neurolog\u00eda.<\/h4>\n<p>&nbsp;<\/p>\n<h4>Para m\u00e1s informaci\u00f3n, no dude en contactar a nuestro equipo m\u00e9dico en <a href=\"mailto:medical@moleac.com\">medical@moleac.com<\/a><\/h4>\n[\/vc_column_text][divider line_type=\u00bbFull Width Line\u00bb line_thickness=\u00bb1&#8243; divider_color=\u00bbaccent-color\u00bb animate=\u00bbyes\u00bb custom_height=\u00bb30&#8243; custom_height_tablet=\u00bb20&#8243; custom_height_phone=\u00bb10&#8243;][\/vc_column][\/vc_row][vc_row type=\u00bbin_container\u00bb full_screen_row_position=\u00bbmiddle\u00bb column_margin=\u00bbnone\u00bb column_direction=\u00bbdefault\u00bb column_direction_tablet=\u00bbdefault\u00bb column_direction_phone=\u00bbdefault\u00bb bg_color=\u00bbrgba(255,255,255,0.35)\u00bb scene_position=\u00bbcenter\u00bb top_padding=\u00bb40&#8243; top_padding_tablet=\u00bb30&#8243; top_padding_phone=\u00bb20&#8243; text_color=\u00bbdark\u00bb text_align=\u00bbleft\u00bb row_border_radius=\u00bbnone\u00bb row_border_radius_applies=\u00bbbg\u00bb overflow=\u00bbvisible\u00bb overlay_strength=\u00bb0.3&#8243; gradient_direction=\u00bbleft_to_right\u00bb shape_divider_color=\u00bb#ffffff\u00bb shape_divider_position=\u00bbboth\u00bb shape_divider_height=\u00bb800&#8243; bg_image_animation=\u00bbnone\u00bb shape_type=\u00bbtriangle\u00bb gradient_type=\u00bbdefault\u00bb][vc_column column_padding=\u00bbno-extra-padding\u00bb column_padding_tablet=\u00bbinherit\u00bb column_padding_phone=\u00bbinherit\u00bb column_padding_position=\u00bball\u00bb column_element_direction_desktop=\u00bbdefault\u00bb column_element_spacing=\u00bbdefault\u00bb desktop_text_alignment=\u00bbdefault\u00bb tablet_text_alignment=\u00bbdefault\u00bb phone_text_alignment=\u00bbdefault\u00bb background_color_opacity=\u00bb1&#8243; background_hover_color_opacity=\u00bb1&#8243; column_backdrop_filter=\u00bbnone\u00bb column_shadow=\u00bbnone\u00bb column_border_radius=\u00bbnone\u00bb column_link_target=\u00bb_self\u00bb column_position=\u00bbdefault\u00bb gradient_direction=\u00bbleft_to_right\u00bb overlay_strength=\u00bb0.3&#8243; width=\u00bb1\/1&#8243; tablet_width_inherit=\u00bbdefault\u00bb animation_type=\u00bbdefault\u00bb bg_image_animation=\u00bbnone\u00bb border_type=\u00bbsimple\u00bb column_border_width=\u00bbnone\u00bb column_border_style=\u00bbsolid\u00bb column_padding_type=\u00bbdefault\u00bb gradient_type=\u00bbdefault\u00bb][tabbed_section style=\u00bbminimal_flexible\u00bb tab_color=\u00bbextra-color-gradient-1&#8243; vs_content_animation=\u00bbfade\u00bb vs_link_animation=\u00bbopacity\u00bb vs_navigation_alignment=\u00bbleft\u00bb vs_navigation_width_2=\u00bb25%\u00bb vs_navigation_func=\u00bbdefault\u00bb vs_navigation_width=\u00bbregular\u00bb vs_navigation_spacing=\u00bb15px\u00bb vs_navigation_mobile_display=\u00bbvisible\u00bb vs_tab_spacing=\u00bb5%\u00bb icon_size=\u00bb24&#8243;][tab icon_family=\u00bbsteadysets\u00bb title=\u00bbI. Ischemic Stroke\u00bb id=\u00bb1746438664263-9&#8243; tab_id=\u00bb1746438664264-2&#8243; icon_steadysets=\u00bbsteadysets-icon-files\u00bb][vc_column_text css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h3>I. Ischemic Stroke<\/h3>\n<h2><span style=\"color: #19388a;\"><b>Clinical data \u2013 Efficacy &amp; Safety<br \/>\n<\/b><\/span><\/h2>\n[\/vc_column_text][divider line_type=\u00bbFull Width Line\u00bb line_thickness=\u00bb2&#8243; divider_color=\u00bbdefault\u00bb][vc_row_inner column_margin=\u00bbdefault\u00bb column_direction=\u00bbdefault\u00bb column_direction_tablet=\u00bbdefault\u00bb column_direction_phone=\u00bbdefault\u00bb top_padding=\u00bb3%\u00bb constrain_group_1=\u00bbyes\u00bb bottom_padding=\u00bb3%\u00bb top_padding_tablet=\u00bb3%\u00bb constrain_group_3=\u00bbyes\u00bb bottom_padding_tablet=\u00bb3%\u00bb top_padding_phone=\u00bb3%\u00bb constrain_group_5=\u00bbyes\u00bb bottom_padding_phone=\u00bb3%\u00bb text_align=\u00bbleft\u00bb row_position=\u00bbdefault\u00bb row_position_tablet=\u00bbinherit\u00bb row_position_phone=\u00bbinherit\u00bb overflow=\u00bbvisible\u00bb pointer_events=\u00bball\u00bb][vc_column_inner column_padding=\u00bbno-extra-padding\u00bb column_padding_tablet=\u00bbinherit\u00bb column_padding_phone=\u00bbinherit\u00bb column_padding_position=\u00bball\u00bb column_element_direction_desktop=\u00bbdefault\u00bb column_element_spacing=\u00bbdefault\u00bb desktop_text_alignment=\u00bbdefault\u00bb tablet_text_alignment=\u00bbdefault\u00bb phone_text_alignment=\u00bbdefault\u00bb background_color_opacity=\u00bb1&#8243; background_hover_color_opacity=\u00bb1&#8243; column_backdrop_filter=\u00bbnone\u00bb column_shadow=\u00bbnone\u00bb column_border_radius=\u00bbnone\u00bb column_link_target=\u00bb_self\u00bb overflow=\u00bbvisible\u00bb gradient_direction=\u00bbleft_to_right\u00bb overlay_strength=\u00bb0.3&#8243; width=\u00bb1\/2&#8243; tablet_width_inherit=\u00bbdefault\u00bb animation_type=\u00bbdefault\u00bb bg_image_animation=\u00bbnone\u00bb border_type=\u00bbsimple\u00bb column_border_width=\u00bbnone\u00bb column_border_style=\u00bbsolid\u00bb][vc_video link=\u00bbhttps:\/\/www.youtube.com\/watch?v=aLTL46iKg6g\u00bb align=\u00bbcenter\u00bb css=\u00bb\u00bb][\/vc_column_inner][vc_column_inner column_padding=\u00bbno-extra-padding\u00bb column_padding_tablet=\u00bbinherit\u00bb column_padding_phone=\u00bbinherit\u00bb column_padding_position=\u00bball\u00bb column_element_direction_desktop=\u00bbdefault\u00bb column_element_spacing=\u00bbdefault\u00bb desktop_text_alignment=\u00bbdefault\u00bb tablet_text_alignment=\u00bbdefault\u00bb phone_text_alignment=\u00bbdefault\u00bb background_color_opacity=\u00bb1&#8243; background_hover_color_opacity=\u00bb1&#8243; column_backdrop_filter=\u00bbnone\u00bb column_shadow=\u00bbnone\u00bb column_border_radius=\u00bbnone\u00bb column_link_target=\u00bb_self\u00bb overflow=\u00bbvisible\u00bb gradient_direction=\u00bbleft_to_right\u00bb overlay_strength=\u00bb0.3&#8243; width=\u00bb1\/2&#8243; tablet_width_inherit=\u00bbdefault\u00bb animation_type=\u00bbdefault\u00bb bg_image_animation=\u00bbnone\u00bb border_type=\u00bbsimple\u00bb column_border_width=\u00bbnone\u00bb column_border_style=\u00bbsolid\u00bb][\/vc_column_inner][\/vc_row_inner][vc_column_text css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4 class=\"et_pb_toggle_title\"><strong>NeuroAiD in Stroke Recovery.<\/strong><\/h4>\n<div class=\"et_pb_toggle_content clearfix\">\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This case series report deals with 10 patients who received NeuroAiD after an ischemic stroke as confirmed on brain imaging (MRI). Conducted in an outpatient private clinic in Mount Alvernia Hospital in Singapore, the report suggests that NeuroAiD can be considered as an add-on treatment to other medications including anti-platelet, warfarin, lipid-lowering, anti-hypertensive, anti-diabetic, and antidepressant medications.<\/p>\n<\/div>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Siow C, Eur Neurol 2008. DOI: 10.1159\/000155220&#8243; url=\u00bbhttps:\/\/karger.com\/ene\/article\/60\/5\/264\/124087\/Neuroaid-in-Stroke-Recovery\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1746435516366{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4 class=\"et_pb_toggle_title\"><strong>NeuroAiD Danqi Piantang Jiaonang Does Not Modify Hemostasis, Hematology, and Biochemistry in Normal Subjects and Stroke Patients.<br \/>\n<\/strong><\/h4>\n<div class=\"et_pb_toggle_content clearfix\">\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">NeuroAiD does not significantly affect hematological, hemostatic, and biochemical parameters in normal and stroke patients. Clinical parameters and expected effects of aspirin are not altered by co-administration of the drug even when started and maintained at the early stage of acute stroke.<\/p>\n<\/div>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Gan R, et al. Cerebrovasc Dis 2008. DOI: 10.1159\/000126919&#8243; url=\u00bbhttps:\/\/karger.com\/ced\/article-abstract\/25\/5\/450\/69181\/Danqi-Piantan-Jiaonang-Does-Not-Modify-Hemostasis?redirectedFrom=PDF\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744362798608{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4><strong>NeuroAiD (Danqi Piantang Jiaonang), a Traditional Chinese Medicine, in Poststroke Recovery.<br \/>\n<\/strong><\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The paper reports the pooled analysis of two randomized controlled clinical trials (initial stroke trials in China) that included 605 patients recruited between 2 weeks and 6 months after their stroke. The results show that patients on NeuroAiD have 2.4 times more chances of achieving independence after 1 month of treatment, and have a 25% better recovery in motor impairments. No serious adverse event was reported.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Chen C, et al. Stroke 2009. DOI: 10.1161\/STROKEAHA.108.531616&#8243; url=\u00bbhttps:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.108.531616&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744362914395{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4><strong>A Double-Blind, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of the Traditional Chinese Medicine NeuroAiD (MLC601) in Enhancing Recovery after Stroke (TIERS).<\/strong><\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The aim of this phase II double-blind placebo controlled study was to investigate the efficacy of NeuroAiD on motor recovery in ischemic stroke patients using rehabilitation endpoints in order to provide predictive information for further larger trials. In this clinical trial, 20 patients within 1 month post-stroke received 4 capsules of NeuroAiD 3 times a day for 4 weeks and 20 other patients received placebo. While no statistical significance was detected for all primary and secondary endpoints due to the small sample size, subgroup analysis show trends for better outcome with NeuroAiD for more severe strokes, posterior strokes, and strokes with potential for recovery at 8 weeks.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Kong KH, et al. Cerebrovasc Dis 2009. DOI: 10.1159\/000247001&#8243; url=\u00bbhttps:\/\/karger.com\/ced\/article-abstract\/28\/5\/514\/58031\/A-Double-Blind-Placebo-Controlled-Randomized-Phase?redirectedFrom=fulltext\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744363045621{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4><strong>Safety Profile of MLC601 (NeuroAiD) in Acute Ischemic Stroke Patients: A Singaporean Substudy of the Chinese Medicine NeuroaiD Efficacy on Stroke Recovery Study.<\/strong><\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This study on 114 patients with acute ischemic stroke randomized within 48 hours of onset shows that serious adverse events (SAEs) were similar between the group treated with placebo and the group treated with MLC601. The SAEs reported were those commonly seen in stroke patients. There were neither statistically or clinically significant differences between treatment groups in biochemical, haematological, or electrocardiogram tests at 3 months, nor any statistically or clinically significant differences in the absolute and relative changes of the various parameters between baseline and 3 months. Thus, MLC601 is safe for patients with acute stroke receiving a 3-month treatment.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Young SHY, et al. Cerebrovasc Dis 2010. DOI: 10.1159\/000313398&#8243; url=\u00bbhttps:\/\/www.researchgate.net\/publication\/43160195_Safety_Profile_of_MLC601_Neuroaid_R_in_Acute_Ischemic_Stroke_Patients_A_Singaporean_Substudy_of_the_Chinese_Medicine_Neuroaid_Efficacy_on_Stroke_Recovery_Study\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744363250682{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4><strong>Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial.<br \/>\n<\/strong><\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This study of 150 Iranian patients with a recent ischemic stroke (within 1 month) shows that MLC601 improves motor recovery as early as 4 weeks and persisted up to 12 weeks after stroke. Moreover, good tolerability to treatment was shown and adverse events were mild and transient. No severe adverse event leading to drug discontinuation was reported.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Harandi AA, et al. Stroke Res Treat 2011. DOI: 10.4061\/2011\/721613&#8243; url=\u00bbhttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3138057\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744363354236{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4><strong>The effect of NeuroAiD (MLC601) on cerebral blood flow velocity in subjects\u2019 post brain infarct in the middle cerebral artery territory.<\/strong><\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This randomized double-blind placebo-controlled study recruited 80 patients within 1 week of stroke, of which 40 received 4 capsules of NeuroAiD 3 times a day and 40 others received placebo for 3 months. The subjects were recruited at Ahvaz Golestan Hospital in Iran from April 2009 to March 2010. This study shows that MLC601 improves cerebral blood flow velocity in post-cerebral infarction subjects better than in the control group. This is associated with more improvement in functional outcome (Barthel Index of activities of daily living) as compared to placebo at 3 months.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Shahripour RB, et al. Eur Intern Med 2011. DOI: 10.1016\/j.ejim.2011.01.002&#8243; url=\u00bbhttps:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0953620511000070&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744878792403{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4><strong>NeuroAiD (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia.<br \/>\n<\/strong><\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">In the clinic, the natural recovery rate of homonymous hemianopsia caused by occipital lobe infarction is low. This prospective study compared the effects of NeuroAiD (MLC601) versus piracetam in improving visual field defects in 40 patients matched for age and sex within 1 week of PCA infarction with pure homonymous hemianopsia. After 3 months of treatment, the findings suggest that MLC601 is superior to piracetam for reducing quantitative visual field defects in homonymous hemianopsia patients.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Ghandehari K, et al. Neural Regen Res 2011. DOI: 10.3969\/j.issn.1673-5374.2011.06.003&#8243; url=\u00bbhttps:\/\/www.researchgate.net\/publication\/289309076_NeuroAid_MLC601_versus_piracetam_in_the_recovery_of_post-infarct_homonymous_hemianopsia\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744878889140{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4><strong>The Use of NeuroAiD (MLC601) in Post ischemic Stroke Patients.<br \/>\n<\/strong><\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This paper aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke. This was a retrospective cohort study comparing 30 post-stroke patients given open-label MLC601 for three months and 30 matching patients who did not receive MLC601 from the Stroke Data Bank. There were positive results from this study: NeuroAiD has been shown to improve functional recovery at 3 months post-ischemic stroke.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Navarro JC, et al. Rehabil Res Pract 2012. DOI: 10.1155\/2012\/506387&#8243; url=\u00bbhttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3532866\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744878962045{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4><strong>Effects of MLC601 on Early Vascular Events in Patients After Stroke: The CHIMES study.<br \/>\n<\/strong><\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This publication is a post-hoc analysis performed on data from subjects included in the CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study. The CHIMES study is an academic international double-blind placebo-controlled clinical trial which treated and monitored 1100 patients from several countries who had suffered an ischemic stroke of intermediate severity within 72 hours, for 3 months. Early vascular events were defined as a composite of recurrent stroke, acute coronary syndrome, and vascular death occurring within 3 months of stroke onset. The research concluded that the risk of early vascular events during the 3-month follow-up was significantly reduced by half in the MLC601 group as compared to the placebo group without an increase in nonvascular deaths. Kaplan\u2013Meier survival analysis demonstrated the difference in risk as early as the first 14 days after stroke.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Chen C, et al. Stroke 2013. DOI: 10.1161\/STROKEAHA.113.003226&#8243; url=\u00bbhttps:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.113.003226&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744879056666{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Efficacy and Safety of MLC601 (NeuroAiD), a Traditional Chinese Medicine, in Poststroke Recovery: A Systematic Review.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This publication updates the 2-study meta-analysis published in Stroke journal in 2009 with all clinical data available since on NeuroAiD and provides an overall assessment of the effects of NeuroAiD in improving functional and motor outcomes by the end of treatment. In a systematic review this paper shows that previous studies on NeuroAiD in ischemic stroke in general were of low risk of bias. The meta-analysis showed a statistically significant beneficial effect in favor of NeuroAiD on functional outcome when assessed at the end of study treatment. Although the results did not reach statistical significance, the overall effects on motor recovery were also in favor of NeuroAiD.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Siddiqui FJ, et al. Cerebrovasc Dis 2013. DOI: 10.1159\/000346231&#8243; url=\u00bbhttps:\/\/www.karger.com\/Article\/FullText\/346231&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744879135352{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Chinese Medicine Neuroaid Efficacy on Stroke Recovery: A Double-Blind, Placebo-Controlled, Randomized Study.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The CHIMES study is an academic international double-blind placebo-controlled clinical trial which treated and monitored 1100 patients from several countries who had suffered an ischemic stroke of intermediate severity within 72 hours, for 3 months. The research concluded that NeuroAiD is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity. However the results of the study confirmed the overall benefit of NeuroAiD in stroke recovery and showed that treatment effect for achieving functional independence was greater among non-acute strokes, consistent with previous studies. In addition the study showed that NeuroAiD had an excellent safety profile.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Chen C, et al. Stroke 2013. DOI: 10.1161\/STROKEAHA.113.002055&#8243; url=\u00bbhttps:\/\/www.ahajournals.org\/doi\/10.1161\/strokeaha.113.002055&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744879217737{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>NeuroAiD\u2122 (MLC601, MLC901): a new bench-to-bedside approach to the treatment of Ischemic Brain Injury.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This paper reviews the important findings on NeuroAiD\u2122, from pharmacological properties to efficacy and safety data in Stroke recovery. It reminds that NeuroAiD has demonstrated neurorestorative and neuroprotective properties and this justifies its use from the postacute to chronic phase of stroke. Clinical benefits have shown that it helps achieve functional independence with 63% increase in the odds of achieving independence in patients with established deficits and enhances recovery of motor functions. In addition, NeuroAiD offers a better protection by reducing early cardiovascular events and deaths by 50% after a stroke.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Dib M, et al. European Journal of Medicinal Plants 2014. DOI: 10.9734\/EJMP\/2015\/13192&#8243; url=\u00bbhttps:\/\/www.semanticscholar.org\/paper\/NeuroAiD-TM-(-MLC-601-%2C-MLC-901-)-%3A-A-New-Approach-Dib-Zahra\/8c74529774ef766d52cf635a7a0ea3a9c701e085&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744879296510{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Baseline characteristics and treatment response of patients from the Philippines in the CHIMES study.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This publication is a pre-planned analysis performed on subjects from the Philippines included in the CHIMES Study. The authors found a statistically significant treatment effect in favour of NeuroAiD\u2122 in the primary outcome of mRS and other secondary outcomes (NIHSS and Barthel Index). This result was likely attributable to the inclusion of patients with more severe stroke and longer delay from stroke onset to treatment initiation in the Philippines cohort. Thus the favourable treatment of NeuroAiD was best demonstrated among postacute stroke patients with moderate severity.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Navarro J, et al. Int J Stroke 2014. DOI: 10.1111\/ijs.12324&#8243; url=\u00bbhttps:\/\/journals.sagepub.com\/doi\/10.1111\/ijs.12324&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744879367480{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This study on 150 patients with acute ischemic stroke within 1 week of onset demonstrates the long-term (up to 6 months) safety of NeuroAiD in a Caucasian population. While mild nausea was more commonly reported in the NeuroAiD group, none of the reported adverse events were serious or required discontinuation of treatment. There was no significant change observed in blood pressure, hematologic, hepatic, and renal functions during treatment with NeuroAid and up to 3 months after completion of a 3-month regimen. These data confirm the excellent safety profile of NeuroAiD in patients with acute ischemic stroke during treatment and long after completion of treatment.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Shahripour RB, et al. Chin J Integr Med 2014. DOI: 10.1007\/s11655-014-1687-8&#8243; url=\u00bbhttps:\/\/link.springer.com\/article\/10.1007\/s11655-014-1687-8&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744879476454{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD).<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The authors\u2019 purpose was to verify if patient selection based on two prognostic actors (ie, stroke severity and time to treatment) improves detection of a treatment effect with MLC601. Analyses were performed using data from the CHIMES Study (international, randomized, placebo-controlled, double-blind trials comparing MLC601 to placebo in patients with ischemic stroke of intermediate severity in the preceding 72 hours). MLC601 treatment effects were much higher in the subgroups with prognostic factors than for the entire group and the highest treatment effect was seen among patients with both prognostic factors. It can be concluded that patient selection appears to be an important factor for consideration when designing clinical trials in stroke to better reveal the treatment effect and provides new insights for futures trials.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Venketasubramanian N, et al. Journal of Evidence-Based Medicine 2015. DOI: 10.1111\/jebm.12170&#8243; url=\u00bbhttps:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/jebm.12170&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744879578373{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Prognostic Factors and Treatment Effect in the CHIMES Study.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This publication is a post-hoc analysis performed on CHIMES study patients. The authors have identified predictors of poorer mRS at 3 months (Age &gt; 60; Female sex; Baseline NIHSS 10-14; Stroke onset to initiation of MLC601 &gt; 48h) and have shown that NeuroAiD\u2122 treatment effect is statistically significant for patients with 2 or more predictors of poorer outcome. Hence this paper illustrates NeuroAiD\u2122 efficacy at 3 months, which is best demonstrated among patients with poorer prognosis.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Chankrachang S, et al. J. of Stroke and Cerebro Diseases 2015. DOI: 10.1016\/j.jstrokecerebrovasdis.2014.11.017&#8243; url=\u00bbhttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S105230571400576X\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744879663412{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>CHInese Medicine NeuroAiD Efficacy on Stroke Recovery \u2013 Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The CHIMES-E study, a planned extension study of the CHIMES study, aimed to evaluate the effects of an initial 3-month treatment with NeuroAiD on long-term outcomes of up to 2 years. This study has showed that NeuroAiD increases significantly the odds of achieving functional independence at 6 months and persisted up to 18 months after a stroke, as measured by mRS dichotomy 0-1. It also provided further long-term safety data on NeuroAiD, even when combined with other stroke treatments. The authors concluded that an initial 3-month treatment with NeuroAiD increased the odds of functional independence after a stroke, \u201cproviding level 1 evidence of benefit in ischaemic stroke\u201d*.<br \/>\n<i>*Venketasubramanian N, et al. As presented at ESOC Glasgow and ESC Vienna 2015<\/i>[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Venketasubramanian N, et al. Cerebrovascular Diseases 2015. DOI: 10.1159\/000382082&#8243; url=\u00bbhttps:\/\/karger.com\/ced\/article\/39\/5-6\/309\/77205\/CHInese-Medicine-NeuroAiD-Efficacy-on-Stroke\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744879756100{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD\u2122) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery \u2013 Extension Study.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This is a sub-analysis of the CHIMES-E study. The researchers aimed to evaluate the recovery pattern and the influence of prognostic factors on treatment effect of NeuroAiD over 2 years. The sustained benefits of NeuroAiD over 2 years were due to more subjects with poorer prognosis improving to functional independence at month 6 and beyond compared to placebo. Selection of subjects with poorer prognosis, particularly those with more severe NIHSS score and longer OTT delay, as well as a long follow-up period, may improve the power of future trials investigating the treatment effect of neuroprotective or neurorestorative therapies.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Venketasubramanian N, et al. Cerebrovascular Diseases 2016. DOI: 10.1159\/000452285&#8243; url=\u00bbhttps:\/\/karger.com\/ced\/article\/43\/1-2\/36\/77397\/Prognostic-Factors-and-Pattern-of-Long-Term\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744880021856{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Comparison Between the Original and Shortened Versions of the National Institutes of Health Stroke Scale in Ischemic Stroke Patients of Intermediate Severity.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The National Institutes of Health Stroke Scale (NIHSS) is composed of 15 items. The purpose of this study was to compare the measurement properties of the original NIHSS with shortened versions (including only 11, 8 and 5 items). The analyses were performed using the data from the CHIMES study at Day 10 and 3 months. The original 15-item NIHSS, which can be performed easily over a few minutes, retained information that made it more discriminative and responsive to change than the shortened versions. The authors recommend to use the full version NIHSS, to evaluate patients\u2019 stroke severity in clinical trials.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Lee CF, et al. Stroke 2016. DOI: 10.1161\/STROKEAHA.115.011657&#8243; url=\u00bbhttps:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.115.011657&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744880095912{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Durability of the beneficial effect of MLC601 (NeuroAiD\u2122) on functional recovery among stroke patients from the Philippines in the CHIMES and CHIMES-E studies.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">A pre-specified country analysis of subjects from the Philippines in the CHInese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) Study, published in 2014, showed significantly improved functional and neurological outcomes on NeuroAiD at month 3. With this new analysis, the researchers showed that the beneficial effect of NeuroAiD seen at month 3 in the Filipino cohort is durable up to two years after stroke.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Navarro JC, et al. International Journal of Stroke 2016. DOI: 10.1177\/1747493016676615&#8243; url=\u00bbhttps:\/\/journals.sagepub.com\/doi\/10.1177\/1747493016676615&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744880177748{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Sex and the treatment effect in the Chinese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) trial.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The National Institutes of Health Stroke Scale (NIHSS) is composed of 15 items. The purpose of this study was to compare the measurement properties of the original NIHSS with shortened versions (including only 11, 8 and 5 items). The analyses were performed using the data from the CHIMES study at Day 10 and 3 months. The original 15-item NIHSS, which can be performed easily over a few minutes, retained information that made it more discriminative and responsive to change than the shortened versions. The authors recommend to use the full version NIHSS, to evaluate patients\u2019stroke severity in clinical trials.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Fabia\u00f1a NL, et al. Journal of Clinical Neuroscience 2016. DOI: 10.1016\/j.jocn.2016.04.013&#8243; url=\u00bbhttps:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0967586816303691&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744881236283{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Effect of Combined Treatment with MLC601 (NeuroAiD\u2122) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMES-E Studies.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">In this study, the CHIMES investigators assess the effects of combining NeuroAiD and rehabilitation. While patients show substantial neurological improvement due to endogenous mechanisms after stroke, they are often not sufficient to achieve complete recovery in many patients. Hence neurorehabilitation remains one of the cornerstones for poststroke management. NeuroAiD has been shown to enhance the inherent neurorestorative and neurorecovery mechanisms after stroke. This paper reports a more significant effect size in the NeuroAiD and persistent rehabilitation vs placebo and persistent rehabilitation group, in comparison with the NeuroAiD vs Placebo effect size in the overall population. NeuroAiD and rehabilitation together can enable more than double the chance to reach independence at 6 months and 1 year. This study supports a probable beneficial effect of combining NeuroAiD and rehabilitation brain repair processes.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Suwanwela et al. Cerebrovasc Dis 2018. DOI: 10.1159\/000492625&#8243; url=\u00bbhttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6214602\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744881338402{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Predictors of Neurological and Functional Recovery in Patients with Moderate to Severe Ischaemic Stroke.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Murie-Fernandez M &amp; Molleda Marzo M. Stroke Res Treat 2020. doi:10.1155\/2020\/1419720.\u00bb url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/32411341\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744881414159{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Frequency and clinical impact of serious adverse events (SAE) on post-stroke recovery with NeuroAiD (MLC601) vs. placebo: the CHIMES study.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This exploratory post-hoc analysis from the CHIMES study compared MLC601 vs. placebo in terms of serious adverse events (SAEs) and their clinical impact. Among 1087 subjects from CHIMES, there were 135 subjects with SAEs: 60 on MLC601 and 75 on placebo. Subjects on MLC601 had lower rates of harmful clinical impacts. The rate of subjects with prolonged hospitalisation was threefold lower with MLC601. These findings could translate to reduced healthcare burden and reduced medical costs from stroke.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Venketasubramanian N, Moorakonda RB, Lu Q et al. Cerebrovasc Dis 2020. DOI: 10.1159\/000506070&#8243; url=\u00bbhttps:\/\/karger.com\/ced\/article\/49\/2\/192\/77316\/Frequency-and-Clinical-Impact-of-Serious-Adverse\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744881590037{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Ischemic stroke and savings in time to achieve functional recovery: Experience from NeuroAiD<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">Using data from a multi-centre, randomised, double-blind, placebo-controlled trial of a neuro-repair treatment (NeuroAiD\/MLC601) with a long-term follow-up, this study analysed the savings in time to functional recovery. The results showed that approximately 40% cumulative incidence of functional recovery was achieved within 6 months after stroke onset in the MLC601 group versus 24 months in the placebo group. The main findings are that MLC601 reduced the time to achieve functional recovery 18 months earlier compared to placebo.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: J. Cardiovasc. Dev. Dis. 2023, 10(3), 117; https:\/\/doi.org\/10.3390\/jcdd10030117&#8243; url=\u00bbhttps:\/\/www.mdpi.com\/2308-3425\/10\/3\/117&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744882975579{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>The Use of MLC901 in Combination with Anticoagulant among an Eastern European Cohort &#8211; Real World Data from NeuroAiD Safe Treatment Registry (NeST Registry).<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Arsovska A, et al. Journal of Clinical Research 2023.\u00bb url=\u00bbhttps:\/\/www.hilarispublisher.com\/open-access\/the-use-of-mlc901-in-combination-with-anticoagulant-among-an-eastern-european-cohort-real-world-data-from-neuroaid-safe-treatment&#8211;97126.html\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744883042385{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Association between Baseline NIHSS Limb Motor Score and Functional Recovery after Stroke: Analysis Based on a Multicountry Dataset.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Chen C, et al. Cerebrovascular Diseases 2023.\u00bb url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/35908546\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744883105905{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Cost-effectiveness of MLC601 in post-stroke functional recovery compared with placebo &#8211; the CHIMES &amp; CHIMES-E studies.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Chen C, et al. BMC Health Serv Res 2024.\u00bb url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/39334395\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744883196243{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Translational Medicine in Acute Ischemic Stroke and Traumatic Brain Injury\u2014NeuroAiD Trials, from Traditional Beliefs to Evidence-Based Therapy.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Venketasubramanian N, et al. Biomolecules 2024.\u00bb url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/38927083\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1744883272496{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>A systematic-search-and-review of registered pharmacological therapies investigated to improve neuro-recovery after a stroke<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Lee TH, et al. Front. Neurol, 2024&#8243; url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/38356890\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][\/tab][tab icon_family=\u00bbsteadysets\u00bb title=\u00bbII. Traumatic Brain Injury\u00bb id=\u00bb1746438664668-8&#8243; tab_id=\u00bb1746438664669-10&#8243; icon_steadysets=\u00bbsteadysets-icon-files\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h3>II. Traumatic Brain Injury<\/h3>\n<h2><span style=\"color: #19388a;\"><b>Clinical data \u2013 Efficacy &amp; Safety<\/b><\/span><\/h2>\n[\/vc_column_text][divider line_type=\u00bbFull Width Line\u00bb line_thickness=\u00bb2&#8243; divider_color=\u00bbdefault\u00bb animate=\u00bbyes\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>MLC901 (NeuroAiD\u2122II) for cognition after traumatic brain injury: a pilot randomized clinical trial.<\/h4>\n<div class=\"et_pb_toggle_content clearfix\">\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This was a 9-month pilot, randomized placebo-controlled clinical trial to examine the safety and potential effects of the herbal supplement MLC901 (NeuroAiD II) on cognitive functioning following TBI. As rersistent cognitive deficits have been reported to affect 15 \u201340% of adults post-TBI, investigators wanted to evaluate the effects of MLC901 in these patients. This study demonstrated that MLC901 was safe and well tolerated post\u2010TBI. This study provided Class I\/II evidence that, for patients with mild to moderate TBI, 6 months of MLC901 improved cognitive functioning.<\/p>\n<\/div>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb text=\u00bbPublication: A. Theadom et al. Eur J Neurol. 2018 Apr 3. DOI: 10.1111\/ene.13653&#8243; url=\u00bbhttps:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.13653&#8243; css_animation=\u00bbfadeIn\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1744885840384{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Case Report on the Use of MLC601 (NeuroAiD) in Neurosurgical Pathologies.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb text=\u00bbPublication: Yeo TT, et al. Poster WSC Seoul 2010.\u00bb url=\u00bbhttps:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.13653&#8243; css_animation=\u00bbfadeIn\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746424597424{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Clinical Outcomes of MLC601 (NeuroAiD\u2122) in Traumatic Brain Injury: A Pilot Study.<\/h4>\n<div class=\"et_pb_toggle_content clearfix\">\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This randomized controlled trial included 32 subjects with non-surgical moderate traumatic brain injury (TBI) allocated to receive standard TBI treatment with or without MLC601 over three months. The MLC601 group had a numerically higher Glasgow Outcome Scale (GOS) score than the control group at all observation timepoints. The Barthel Index (BI) values indicated a significant improvement for the MLC601 group at M3, with a favourable trend at M6. No adverse effects were noted. MLC601 showed potential for a positive effect on TBI outcome with no adverse effects.<\/p>\n<\/div>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb text=\u00bbPublication: Fauzi AA, Prihastomo KT, Ranuh IGMAR et al. Brain Sci 2020;10;60:1-9. DOI: 10.3390\/brainsci10020060&#8243; url=\u00bbhttps:\/\/www.mdpi.com\/2076-3425\/10\/2\/60&#8243; css_animation=\u00bbfadeIn\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746424747748{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>MLC901 for Moderate to Severe Traumatic Brain Injury: Pilot, Randomized, Double-Masked, Placebo-Controlled Trial.<\/h4>\n<div class=\"et_pb_toggle_content clearfix\">\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The study aims to evaluate the efficacy of MLC901 on the neurological outcome of patient after moderate (GCS 9-12) to severe (GCS 3-8) traumatic brain Injury. Patients were randomized to receive MLC901 or placebo for six months with an intention to treat analysis. Assessment was carried out using mRS and GOS at baseline, 3 months and at 6 months follow up. Result showed functional outcome of mRS and GOS at 3 and 6 months were significantly better compared to placebo. The study highlights the promising efficacy of MLC901 in patients suffering from moderate to severe TBI.<\/p>\n<\/div>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb text=\u00bbPublication: Hussein Pakdaman, et al Open access journal of Complementary and Alternative Medicine DOI: 10.32474\/ OAJCAM.2020.02.000148&#8243; url=\u00bbhttps:\/\/lupinepublishers.com\/complementary-alternative-medicine-journal\/fulltext\/mlc901-for-moderate-to-severe-traumatic-brain-injury-pilot-randomized-double-masked.Id.000148.php\u00bb css_animation=\u00bbfadeIn\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746424882603{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Case Report: Use of MLC601 in Severe Traumatic Brain Injury<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb text=\u00bbPublication: Kumar R, et al. Neurosung Cases Rev 2022&#8243; url=\u00bbhttps:\/\/clinmedjournals.org\/articles\/ncr\/neurosurgery-cases-and-reviews-ncr-5-123.php?jid=ncr\u00bb css_animation=\u00bbfadeIn\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746424931988{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>INCOG 2.0 Guidelines for Cognitive Rehabilitation Following Traumatic Brain Injury, Part II: Attention and Information Processing Speed.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb text=\u00bbPublication: Ponsford J, et al. J Head Trauma Rehabil. 2023&#8243; url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/36594858\/\u00bb css_animation=\u00bbfadeIn\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][\/tab][tab icon_family=\u00bbsteadysets\u00bb title=\u00bbIII. Spinal Cord Injury\u00bb id=\u00bb1746438664782-9&#8243; tab_id=\u00bb1746438664782-10&#8243; icon_steadysets=\u00bbsteadysets-icon-files\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h3>III. Spinal Cord Injury<\/h3>\n<h2><span style=\"color: #19388a;\"><b>Clinical data \u2013 Efficacy &amp; Safety<\/b><\/span><\/h2>\n[\/vc_column_text][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Spinal cord injury &#8211; Assessing tolerability and use of combined rehabilitation and NeuroAiD (saturn) Study &#8211; Primary results of an exploratory study.<\/h4>\n<div class=\"et_pb_toggle_content clearfix\">\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This study is an open-label cohort study of patients with severe spinal cord injury (SCI), measured by American Spinal Injury Association (ASIA) Impairment Scale (AIS) A and B. Ten patients experienced 14 adverse events including one serious adverse event and six deaths, none were considered treatment-related. AIS grade improved in 25% of AIS A and 50% of AIS B. The study concluded that NeuroAiD is safe and may have a role in the treatment of patients with SCI.<\/p>\n<\/div>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb text=\u00bbPublication: Carolann Murphy, Florian P. Thomas. (2023) The Journal of Spinal Cord Medicine https:\/\/doi.org\/10.1080\/10790268.2022.2067972&#8243; url=\u00bbhttps:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10790268.2022.2067972&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746428371218{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Long-term outcomes of the spinal cord injury assessing tolerability and use of combine rehabilitation and NeuroAiD (Saturn study)<\/h4>\n<div class=\"et_pb_toggle_content clearfix\">\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This study is a long-term follow-up of an open-label cohort study of patients with severe spinal cord injury (SCI), measured by American Spinal Injury Association (ASIA) Impairment Scale (AIS) A and B. After 6 months of NeuroAiD treatment, patients showed durability of improvement in total motor, sensory and SCIM score. The improvement was maintained until 12, 18 and 24 months.<\/p>\n<\/div>\n[\/vc_column_text][nectar_btn size=\u00bbsmall\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb text=\u00bbPublication: Ramesh Kumar, et al. Journal of Spine Research and Surgery 2023&#8243; url=\u00bbhttps:\/\/www.fortunejournals.com\/articles\/longterm-outcomes-of-the-spinal-cord-injury-assessing-tolerability-and-use-of-combine-rehabilitation-and-neuroaid-saturn-study.html\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][\/tab][tab icon_family=\u00bbsteadysets\u00bb title=\u00bbIV. Cognitive Disorders and Dementia\u00bb id=\u00bb1746438664824-5&#8243; tab_id=\u00bb1746438664825-1&#8243; icon_steadysets=\u00bbsteadysets-icon-files\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h3>IV. Cognitive Disorders and Dementia<\/h3>\n<h2><span style=\"color: #19388a;\"><b>Alzheimer\u2019s Disease<\/b><\/span><\/h2>\n[\/vc_column_text][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Efficacy and Tolerability of MLC601 in Patients with Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The aim of this early stage \u201cproof-of-concept\u201d clinical study was to evaluate the efficacy and tolerability of MLC601 in patients with mild to moderate Alzheimer disease (AD). The results showed that NeuroAiD was well-tolerated even up to 18 months of treatment. This tolerability represents a key improvement compared to current AD treatments, i.e. ChEIs, in which a modest but significant therapeutic effect is often compromised by the occurrence of adverse events and discontinuation of treatment.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Harandi AA, et al. Brit Med Med Res 2013.\u00bb url=\u00bbhttps:\/\/journaljammr.com\/index.php\/JAMMR\/article\/view\/988&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746431265519{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer\u2019s Disease: A Multicenter, Randomized Controlled Trial.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This publication is a multicenter, nonblinded, randomized controlled trial, which included 264 volunteers with AD to evaluate the effectiveness and safety of MLC601 in the treatment of mild to moderate AD as compared to 3 approved cholinesterase inhibitors (ChEIs) including donepezil, rivastigmine and galantamine. This is the second clinical study of NeuroAiD\u2122 effectiveness and safety in Alzheimer disease. In a previous clinical trial study, NeuroAiD\u2122 has demonstrated a favorable tolerability and encouraging effectiveness on cognitive function in Alzheimer disease patients during 18 months of treatment when compared to rivastigmine. In this study, the authors have shown that NeuroAiD\u2122 has favorable effects on cognitive functions during 16 months of follow-up, with improvements on cognitive function specifically observed in the first 8 months of treatment. NeuroAiD\u2122 is as effective as other commonly used Cholinesterase inhibitors (Donepazil, Rivastigmine, Galantamine) in treating cognitive deficits. Finally, NeuroAiD\u2122 has shown a better tolerability profile compared to the 3 ChEIs, which implies a better compliance for patients.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Pakdaman, H et al. Dementia and Geriatric Cognitive Disorders 2015. DOI: 10.1159\/000375295&#8243; margin_bottom=\u00bb30&#8243; url=\u00bbhttps:\/\/europepmc.org\/article\/med\/29042785&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746431463578{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This was an open-label extension study evaluating the efficacy and safety of MLC601 in patients with mild to moderate AD. The rationale behind this study is supported by current evidence on the long-term efficacy of MLC601 in post-stroke recovery, by positive results in the treatment of dementia and minimal cognitive impairment. The efficacy of treating AD patients with MLC601 over 4 years has been demonstrated in the study. Overall, it seems that the safety and efficacy of MLC601 is promising compared to currently prescribed treatments.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Pakdaman et al. Dement Geriatr Cogn Disord Extra 2018. DOI: 10.1159\/000488482&#8243; margin_bottom=\u00bb30&#8243; url=\u00bbhttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5968230\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746431653838{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Alzheimer&#8217;s Disease THErapy With NeuroAiD (ATHENE): A Randomized Double-Blind Delayed-Start Trial<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Christopher L.H. Chen et al. Journal of the American Medical Directors Association, Volume 23, Issue 3, March 2022.\u00bb margin_bottom=\u00bb30&#8243; url=\u00bbhttps:\/\/www.jamda.com\/article\/S1525-8610(21)00938-5\/fulltext\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746431670427{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>A Review of NeuroAiD\u2122II (MLC901) Development in Alzheimer\u2019s Disease Treatment: Promises of A Multimodal Pathway.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Dib M, et al. Journal of Neurology Research Reviews &amp; Reports\u00bb margin_bottom=\u00bb30&#8243; url=\u00bbhttps:\/\/www.onlinescientificresearch.com\/abstract\/a-review-of-neuroaidtm-ii-mlc901-development-in-alzheimerrsquos-disease-treatment-promises-of-a-multimodal-pathway-2072.html\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746431915096{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>A long-term study of NeuroAiD (MLC601, MLC901) in patients with alzheimer disease; an extension &amp; year follow-up study<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">For more than eight years, we studied monotherapy with NeuroAid (MLC601, MLC901) in patients with AD. 8 patients out of 78 patients had mild and temporary adverse events. None of the patients stopped taking their medication because of adverse events related to the study treatment. At the end of the trial, the changes in the mean (\u00b1SD) Mini-Mental State Examination (MMSE) and the Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) were 5.1 (3.09) and 12.5 (10.89), respectively. The study contributes further to the long-term safety and efficacy data of MLC in patients with AD.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Pakdaman Hossein, et al. Alzheimer\u2019s Disease; An Extension 8-year Follow-up Study, Current Aging Science 2023 https:\/\/dx.doi.org\/10.2174\/1874609816666230224111759&#8243; margin_bottom=\u00bb30&#8243; url=\u00bbhttps:\/\/www.eurekaselect.com\/article\/129792&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746434745309{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h2><span style=\"color: #19388a;\"><b>Mild Cognitive Impairment<br \/>\n<\/b><\/span><\/h2>\n[\/vc_column_text][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The researchers decided to conduct this study knowing the promising effect of MLC601 (NeuroAiD) in Alzheimer\u2019s disease. They designed a pilot, randomized, double-blind, placebo-controlled study aiming at evaluating the efficacy and the safety of MLC601 in patients with Mild Cognitive Impairments (MCI). MCI is characterized by a decline of the cognitive function greater than that expected for a person\u2019s age, with a possible progress into dementia. Seventy-two patients were receiving NeuroAiD or placebo during 6 months (M) with an evaluation of global cognitive function performed with two different scales (MMSE and ADAScog) at baseline, M3, and M6 follow-up visits. A repeated-measures analysis carried out based on both scales\u2019 score, showed a statistically significant difference between the placebo and the MLC601 group during the 6 months of follow-up. Overall, the tolerability of the product was good with only 5 patients reporting transient and tolerable gastrointestinal disorders.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Pakdaman H, et al. Dementia and Geriatric Cognitive Disorders 2017. DOI: 10.1159\/000458521&#8243; margin_bottom=\u00bb30&#8243; url=\u00bbhttps:\/\/karger.com\/dee\/article\/7\/1\/136\/96464\/Efficacy-and-Safety-of-MLC601-in-the-Treatment-of\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746434761409{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h2><span style=\"color: #19388a;\"><b>Vascular Dementia<\/b><\/span><\/h2>\n[\/vc_column_text][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>MLC601 in vascular dementia: an efficacy and safety pilot study.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">Following Alzheimer\u2019s disease (AD), Vascular Dementia (VaD) is the second most common cause of dementia in elderly people with lack of available effective treatment. Several studies and clinical trials have demonstrated the benefits of MLC601 (NeuroAiD) in post-stroke recovery and AD. This pilot trial was multicenter, randomized, double-blind, aiming to investigate the efficacy and safety of NeuroAiD in patients suffering from VaD. This is the first study conducted on NeuroAiD to investigate its efficacy in VaD as well as duration of treatment over 24 months. Repeated measures analyses showed that both MMSE and ADAS-cog scores were significantly better in the treatment group at 24 months. This long-term treatment with NeuroAiD was well-tolerated without reported serious adverse events.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Pakdaman H, et al. Neuropsychiatric Disease and Treatment 2017. DOI: 10.2147\/NDT.S145047&#8243; margin_bottom=\u00bb30&#8243; url=\u00bbhttps:\/\/www.dovepress.com\/mlc601-in-vascular-dementia-an-efficacy-and-safety-pilot-study-peer-reviewed-fulltext-article-NDT\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][\/tab][tab icon_family=\u00bbsteadysets\u00bb title=\u00bbV. Preclinical Data \u2013 Pharmacology\u00bb id=\u00bb1746438664970-5&#8243; tab_id=\u00bb1746438664970-8&#8243; icon_steadysets=\u00bbsteadysets-icon-files\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h3>V. Preclinical Data \u2013 Pharmacology<\/h3>\n<h2><span style=\"color: #19388a;\"><b>Stroke<br \/>\n<\/b><\/span><\/h2>\n[\/vc_column_text][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Neuroprotective and neuroproliferative activities of NeuroAiD (MLC601, MLC901), a Chinese medicine, in vitro and in vivo.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The paper describes the results of a series of in vivo and in vitro experiments demonstrating the neuroprotective and neuroproliferative effects of NeuroAiD when given prior to and\/or after injury in rodent models of ischemic stroke and neuronal injuries, human embryonic stem cells, and neuronal cell cultures. It shows how NeuroAiD supports neuroplasticity by its effect on neurogenesis, neuritic outgrowth, and synaptogenesis. NeuroAiD provides a better milieu for post-stroke recovery and decreases neurological impairments<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Heurteaux C, et al. Neuropharmacology 2010. DOI: 10.1016\/j.neuropharm.2010.01.001&#8243; url=\u00bbhttps:\/\/hal.science\/hal-00497701\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746435528166{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>MLC901, a traditional Chinese medicine protects the brain against global ischemia.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The paper describes the results of a series of in vivo experiments demonstrating neuroprotective and neurogenesis effects of MLC901 on hippocampal CA1 region against global ischemia in rodent models of global ischemia. It shows how neuronal protection by MLC901 is likely mediated by the Akt protein (a central mediator in the signal transduction pathway involved in cell survival) and reduction of oxidative stress. MLC901 prevents necrosis and apoptotic cell death induced by global ischemia, enhances neurogenesis, and enhances functional recovery. This makes MLC901 a potential novel therapeutic strategy in treating cognitive and neurological deficits caused by global ischemia from conditions that deprive the brain of oxygen and glucose, such as cardiac arrest.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Quintard H, et al. Neuropharmacology 2011. DOI: 10.1016\/j.neuropharm.2011.05.003&#8243; url=\u00bbhttps:\/\/hal.science\/hal-00726324&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746435535666{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Activation of ATP-sensitive potassium channels as an element of the neuroprotective effects of the Traditional Chinese Medicine MLC901 against oxygen glucose deprivation.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This paper highlights the potency of NeuroAid in neuroprotection with the discovery of a key underlying mechanism of action. The activation by NeuroAid of the ATP-sensitive potassium channel located in the suffering neurons of the brain protects them from death. Indeed, the opening of the channel decreases the excitability of neurons (by hyperpolarization) preventing an overload of calcium and release of excitotoxic glutamate. Besides the beneficial effects in neuroplasticity already published, these results strengthen the interest of NeuroAid in stroke recovery.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Moha Ou Maati H, et al. Neuropharmacology 2012. DOI: 10.1016\/j.neuropharm.2012.05.035&#8243; url=\u00bbhttps:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S002839081200233X?via%3Dihub\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746435543399{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>NeuroAiD: Properties for Neuroprotection and Neurorepair.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This paper reviews the pharmacological effects of NeuroAiD on the normal and ischemic brain and neurons. In vivo and in vitro experiments using mouse model of stroke (focal ischemia), rat model of cardiac arrest (global ischemia) and cortical neurons in culture were reviewed and summarized. In conclusion NeuroAID demonstrated both neuroprotective and neuroregenerative properties in rodent models of focal and global ischemia and in cortical cell cultures.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Heurteaux C, et al. Cerebrovasc Dis 2013. DOI: 10.1159\/000346228&#8243; url=\u00bbhttps:\/\/karger.com\/ced\/article\/35\/Suppl.%201\/1\/76724\/NeuroAiD-Properties-for-Neuroprotection-and\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746435552651{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">NeuroAiD\u2122II (MLC901) has already demonstrated neuroprotective and neuroreparative properties and is also proven to improve long-term post-stroke recovery in human. In humans, vascular remodeling takes place 3 or 4 days after stroke, facilitating the processes of neurorepair. Therapeutic angiogenesis is an approach of regenerative medicine that may help in improving the outcomes of patients after an ischemic stroke. Because the neural and vascular cell crosstalk is important in brain repair, Dr. Catherine Heurteaux and her team at CNRS (National Center for Scientific Research, France) decided to further investigate the effect of MLC901 on vascular remodeling in a model of focal ischemia in mice. This study has provided evidences that MLC901 enhances endothelial cell proliferation and vascular remodeling locally in the ipsilateral infarcted area, but not in the contralateral hemisphere, showing that MLC901 is stimulating only the natural local revascularization process. This key finding highlights the role of MLC901 in stimulating revascularization, neuroprotection and repair of the neurovascular niche after ischemic stroke.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Gandin C, et al. Cerebrovasc Diseases 2016. DOI: 10.1159\/000444810&#8243; url=\u00bbhttps:\/\/karger.com\/ced\/article\/42\/1-2\/139\/77585\/MLC901-Favors-Angiogenesis-and-Associated-Recovery\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746435559534{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Acute and long-term cardioprotective effects of the Traditional Chinese Medicine MLC901 against myocardial ischemia-reperfusion injury in mice.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This in-vivo study conducted by the CNRS (National Center for Scientific Research, France) is providing further evidence of MLC901 (NeuroAiD\u2122II) multimodal mechanism of action and particularly interesting to better understand a possible cardioprotective effect. A previous study, published in Stroke in 2013, demonstrated the benefits of NeuroAiD in reducing the risk of early vascular events in post-stroke victims, up to 3 months following stroke onset (Chen C, et al. Stroke 2013.). The researchers aimed at evaluating the acute and long-term benefits of MLC901 (NeuroAiD\u2122II) in ischemic and reperfused mouse heart models. This paper demonstrates that MLC901 treatment was able to provide acute and long-term cardioprotective effects in a murine model of myocardial ischemia-reperfusion injury in vivo.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Vincent a, et al. Scientific reports 2017. DOI: 10.1038\/s41598-017-14822-x\u00bb url=\u00bbhttps:\/\/www.nature.com\/articles\/s41598-017-14822-x\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746435568051{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>The Traditional Chinese Medicine MLC901 inhibits inflammation processes after focal cerebral ischemia.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This study investigates the potential anti-inflammatory effects of MLC901 (NeuroAiD\u2122II) in a model of transient focal cerebral ischemia in mice (60-min middle cerebral artery occlusion), and analyzes the effect of MLC901 on the different mechanisms that trigger the inflammatory process. MLC901 increases survival after MCAO, reduces the infarct volume, and improves the neurological score. These are in line with previous preclinical results and clinical trials. The major effects of MLC901 are: 1) the reduction of neutrophil recruitment, 2) the reduction of microglia activation, and 3) the reduction of pro-inflammatory mediators (TNF\u03b1, IL6, IL1\u03b2, CCL2) production induced by stroke. The present work confirms that MLC901 significantly protects mice against brain injury after focal ischemia and represents a promising therapeutic strategy for brain injuries, and particularly stroke treatment.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Widmann C, et al. Scientific reports 2018. DOI: 10.1038\/s41598-018-36138-0&#8243; url=\u00bbhttps:\/\/www.nature.com\/articles\/s41598-018-36138-0&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746438538558{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h2><span style=\"color: #19388a;\"><b>Traumatic Brain Injury<\/b><\/span><\/h2>\n[\/vc_column_text][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after Traumatic Brain Injury in rats.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This paper demonstrates how NeuroAiD\u2122 can be beneficial in reducing the deleterious consequences induced by Traumatic Brain Injury (TBI) and highlights NeuroAiD\u2122 properties in a rat model of TBI. This is the first publication on the pharmacological actions of NeuroAiD\u2122 in TBI and in which its multimodal mechanisms as well as its time-effect have been demonstrated. Adding to NeuroAiD\u2122 beneficial effects in ischemic stroke recovery, this work provides evidence that NeuroAiD\u2122 has neuroprotective and neurorestorative actions which lead to an improvement in the recovery of cognitive functions in an animal model of TBI, hence providing a rationale for NeuroAiD\u2122 to improve recovery of patients with TBI.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Quintard H, et al. Neuroscience 2014. DOI: 10.1016\/j.neuroscience.2014.06.047&#8243; url=\u00bbhttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S0306452214005326?via%3Dihub\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746436642026{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Therapeutic Efficacy of NeuroAiD\u2122 (MLC 601), a Traditional Chinese Medicine, in Experimental Traumatic Brain Injury.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">This paper highlights the role of MLC601 in improving recovery as well as affecting microglial activation in a model of rats with induced TBI. Early treatment with MLC601 (1h post-TBI) has shown significantly better benefits in reducing TBI-induced cerebral contusion than a late treatment. Beneficial effects of MLC601 were correlated with reduction in neurological and motor deficits, neuronal apoptosis and microglial activation (microgliosis, morphological transformation of microglia and microglial overexpression of TNF-\u03b1). These results are consistent in part with the beneficial effects of MLC901 in a model of rats with induced TBI already published. This work provides further evidence and a rationale to use MLC601 or MLC901 therapy in improving functional recovery in patients with TBI.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Tsai MC, et al. J Neuroimmune Pharmacol 2014. DOI: 10.1007\/s11481-014-9570-0&#8243; url=\u00bbhttps:\/\/link.springer.com\/article\/10.1007\/s11481-014-9570-0&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746436704547{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>A positive correlation exists between neurotrauma and TGF-\u03b21- containing microglia in rats.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">Many post-Traumatic Brain Injury\u2019s (TBI) processes are mediated by the Transforming growth factor-beta 1 (TGF-\u03b21) expressed by microglial cells. Previous studies identified the activity of NeuroAiD in reducing microglia activation in rats with TBI. This in-vivo studies, conducted on rats, aimed at investigating whether NeuroAiD or Astragaloside (also known to attenuate microglia activation) improves output of TBI by affecting microglial expression of TGF-\u03b21. The researchers found that both NeuroAiD and Astragaloside significantly reduced TBI-induced brain contused volume, neurological severity score and the number of TGF-\u03b21 containing microglia. This is another demonstration of NeuroAiD\u2019s neuroprotective effect, already highlighted in several published pre-clinical studies.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Chio CC, et al. 2016. DOI: 10.1111\/eci.12693&#8243; url=\u00bbhttps:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.12693&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1747207684531{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h2><span style=\"color: #19388a;\"><b>Spinal Cord Injury<br \/>\n<\/b><\/span><\/h2>\n[\/vc_column_text][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>The role of MLC901 in reducing VEGF as a vascular permeability marker in rats with spinal cord injury.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Wahyudi, et al. Annals of Medicine and Surgery 2022.\u00bb url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/35386787\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746437130783{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Effects of Moleac 901 after severe spinal cord injury on chronic phase in Wistar rats.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Wardhana W, et al. Heliyon 2024.\u00bb url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/38601579\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746437196737{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>NeuroAiD\u2122II (MLC901) Promoted Neurogenesis by Activating the PI3K\/AKT\/GSK-3\u03b2 Signaling Pathway in Rat Spinal Cord Injury Models<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Anjum A, et al. Biomedicines 2024.\u00bb url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/39200383\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746438613179{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h2><span style=\"color: #19388a;\"><b>Cognitive Disorders and Dementia<\/b><\/span><\/h2>\n[\/vc_column_text][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>NeuroAiD (MLC601) and Amyloid Precursor Protein Processing.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The purpose of this paper was to investigate the effects of MLC601 (NeuroAiD) on regulation of APP (Amyloid Precursor Protein) processing. Human neuroblastoma cell line SH-SY5Y was used for all experiments. Cells were treated with different concentration of NeuroAiD before assessing changes in the levels of released lactate dehydrogenase (LDH), full-length APP and secreted sAPP\u03b1. In conclusion it appears that NeuroAiD is a possible modulator of APP processing and has implications as a putative therapeutic strategy for the treatment of post stroke dementia and AD.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Lim YA, et al. Cerebrovasc Dis 2013. DOI: 10.1159\/000346236&#8243; url=\u00bbhttps:\/\/www.karger.com\/Article\/Fulltext\/346236&#8243; icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb.vc_custom_1746437435248{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>The effects of MLC901 on tau phosphorylation.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The presence of neurofibrillary tangles (NFTs) in the brain is characteristic of neurodegenerative diseases including Alzheimer\u2019s disease and frontotemporal dementia due to the hyperphosphorylation of the tau protein. The objective of this study was to assess the effects of MLC901 (NeuroAiDTMII) on ameliorating tau phosphorylation at epitopes associated with formation of NFTs. Results support evidence for a role of MLC901 in mediating this effect by inhibiting kinases (GSK3\u03b2 and cdk5) leading to a significant decrease of tau phosphorylation. Previous studies (pre-clinical and clinical) having demonstrated the effect of MLC601 (NeuroAiD) as a promising therapeutic strategy for Alzheimer\u2019s disease, this paper provides a new understanding of its multimodal mechanisms of action in this promising indication.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Lee WT, et al. NeuroReport 2017. DOI: 10.1097\/WNR.0000000000000884&#8243; url=\u00bbhttps:\/\/journals.lww.com\/neuroreport\/Abstract\/2017\/12010\/The_effects_of_MLC901_on_tau_phosphorylation.3.aspx\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][\/tab][tab icon_family=\u00bbsteadysets\u00bb title=\u00bbVI. Others\u00bb id=\u00bb1746438665204-1&#8243; tab_id=\u00bb1746438665204-8&#8243; icon_steadysets=\u00bbsteadysets-icon-files\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h3>VI. Other Neurological Pathologies<\/h3>\n[\/vc_column_text][vc_column_text css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>The NeuroAiD Safe Treatment (NeST) Registry: a protocol.<\/h4>\n<p style=\"text-align: justify; font-size: 18px; line-height: 1.6em;\">The NeuroAiD Safe Treatment (NeST) Registry works as a product registry to provide information on the use of NeuroAiD and monitor its safety in a real world setting. The NeST Registry is a proactive industry-academic effort designed to be as unobtrusive as possible during its assessment hence an online framework was introduced for easier data entry and retrieval of clinical information. The registry also acts as a complement for more accurate pharmacovigilance, essential for patient care and surveillance. Participation is voluntary and patients\u2019 data is anonymous.<\/p>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Venketasubramanian N, et al. BJM Open 2015. DOI: 10.1136\/bmjopen-2015-009866&#8243; url=\u00bbhttps:\/\/bmjopen.bmj.com\/content\/5\/11\/e009866.long\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1746438721201{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Safety And Use Of MLC601\/MLC901 (NeuroAiD) In Primary Intracerebral Hemorrhage: A Cohort Study From The NeuroAiD Safe Treatment Registry.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Kumar R, et al. Brain Sciences 2020.\u00bb url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/32751570\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1746438728534{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo controlled pilot study.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Pakdaman H, et al. Medicine 2023.\u00bb url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/37335674\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][vc_column_text css=\u00bb.vc_custom_1746438735302{margin-top: 5% !important;}\u00bb text_direction=\u00bbdefault\u00bb]\n<h4>Use of MLC901 in cerebral venous sinus thrombosis: Three case reports.<\/h4>\n[\/vc_column_text][nectar_btn size=\u00bbmedium\u00bb open_new_tab=\u00bbtrue\u00bb button_style=\u00bbsee-through-2&#8243; hover_text_color_override=\u00bb#ffffff\u00bb icon_family=\u00bblinecons\u00bb css_animation=\u00bbfadeIn\u00bb text=\u00bbPublication: Arsovska AA, et al. World J Clin Cases 2024.\u00bb url=\u00bbhttps:\/\/pubmed.ncbi.nlm.nih.gov\/38313657\/\u00bb icon_linecons=\u00bbvc_li vc_li-news\u00bb][\/tab][\/tabbed_section][divider line_type=\u00bbFull Width Line\u00bb line_thickness=\u00bb2&#8243; divider_color=\u00bbdefault\u00bb animate=\u00bbyes\u00bb][\/vc_column][\/vc_row][vc_row type=\u00bbin_container\u00bb full_screen_row_position=\u00bbmiddle\u00bb column_margin=\u00bbdefault\u00bb column_direction=\u00bbdefault\u00bb column_direction_tablet=\u00bbdefault\u00bb column_direction_phone=\u00bbdefault\u00bb scene_position=\u00bbcenter\u00bb top_padding=\u00bb50&#8243; text_color=\u00bbdark\u00bb text_align=\u00bbleft\u00bb row_border_radius=\u00bbnone\u00bb row_border_radius_applies=\u00bbbg\u00bb overflow=\u00bbvisible\u00bb overlay_strength=\u00bb0.3&#8243; gradient_direction=\u00bbleft_to_right\u00bb shape_divider_position=\u00bbbottom\u00bb bg_image_animation=\u00bbnone\u00bb shape_type=\u00bb\u00bb][vc_column column_padding=\u00bbno-extra-padding\u00bb column_padding_tablet=\u00bbinherit\u00bb column_padding_phone=\u00bbinherit\u00bb column_padding_position=\u00bball\u00bb column_element_direction_desktop=\u00bbdefault\u00bb column_element_spacing=\u00bbdefault\u00bb desktop_text_alignment=\u00bbdefault\u00bb tablet_text_alignment=\u00bbdefault\u00bb phone_text_alignment=\u00bbdefault\u00bb background_color_opacity=\u00bb1&#8243; background_hover_color_opacity=\u00bb1&#8243; column_backdrop_filter=\u00bbnone\u00bb column_shadow=\u00bbnone\u00bb column_border_radius=\u00bbnone\u00bb column_link_target=\u00bb_self\u00bb column_position=\u00bbdefault\u00bb gradient_direction=\u00bbleft_to_right\u00bb overlay_strength=\u00bb0.3&#8243; width=\u00bb1\/1&#8243; tablet_width_inherit=\u00bbdefault\u00bb animation_type=\u00bbdefault\u00bb bg_image_animation=\u00bbnone\u00bb border_type=\u00bbsimple\u00bb column_border_width=\u00bbnone\u00bb column_border_style=\u00bbsolid\u00bb][vc_column_text css_animation=\u00bbfadeIn\u00bb]<span style=\"color: #333333;\"><strong>Exenci\u00f3n de responsabilidad<\/strong><strong>:<\/strong> \u00a0<em>NeuroAiD\u2122 II\u00a0es una marca comercial de Moleac. MLC601 y MLC901 son 2 formulaciones patentadas diferentes cuya equivalencia farmacol\u00f3gica se ha demostrado y que se denominan NeuroAiD en esta p\u00e1gina web.<\/em><\/span>[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00bbin_container\u00bb full_screen_row_position=\u00bbmiddle\u00bb column_margin=\u00bbdefault\u00bb column_direction=\u00bbdefault\u00bb column_direction_tablet=\u00bbdefault\u00bb column_direction_phone=\u00bbcolumn_reverse\u00bb bg_color=\u00bb#19388a\u00bb scene_position=\u00bbcenter\u00bb top_padding=\u00bb5%\u00bb bottom_padding=\u00bb30&#8243; text_color=\u00bbdark\u00bb text_align=\u00bbleft\u00bb row_border_radius=\u00bbnone\u00bb row_border_radius_applies=\u00bbbg\u00bb overflow=\u00bbvisible\u00bb overlay_strength=\u00bb0.3&#8243; gradient_direction=\u00bbleft_to_right\u00bb enable_shape_divider=\u00bbtrue\u00bb shape_divider_color=\u00bb#ffffff\u00bb shape_divider_position=\u00bbtop\u00bb shape_divider_height=\u00bb80&#8243; bg_image_animation=\u00bbnone\u00bb shape_type=\u00bbcurve\u00bb gradient_type=\u00bbdefault\u00bb][vc_column column_padding=\u00bbno-extra-padding\u00bb column_padding_tablet=\u00bbinherit\u00bb column_padding_phone=\u00bbinherit\u00bb column_padding_position=\u00bball\u00bb top_margin=\u00bb10%\u00bb top_margin_tablet=\u00bb15%\u00bb top_margin_phone=\u00bb5%\u00bb column_element_direction_desktop=\u00bbdefault\u00bb column_element_spacing=\u00bbdefault\u00bb desktop_text_alignment=\u00bbdefault\u00bb tablet_text_alignment=\u00bbdefault\u00bb phone_text_alignment=\u00bbdefault\u00bb background_color_opacity=\u00bb1&#8243; background_hover_color_opacity=\u00bb1&#8243; column_backdrop_filter=\u00bbnone\u00bb column_shadow=\u00bbnone\u00bb column_border_radius=\u00bbnone\u00bb column_link_target=\u00bb_self\u00bb column_position=\u00bbdefault\u00bb gradient_direction=\u00bbleft_to_right\u00bb overlay_strength=\u00bb0.3&#8243; width=\u00bb2\/3&#8243; tablet_width_inherit=\u00bbsmall_desktop\u00bb animation_type=\u00bbdefault\u00bb bg_image_animation=\u00bbnone\u00bb border_type=\u00bbsimple\u00bb column_border_width=\u00bbnone\u00bb column_border_style=\u00bbsolid\u00bb column_padding_type=\u00bbdefault\u00bb gradient_type=\u00bbdefault\u00bb][vc_column_text css_animation=\u00bbbounceIn\u00bb css=\u00bb\u00bb text_direction=\u00bbdefault\u00bb]\n<h3><span style=\"color: #ffffff;\">Averig\u00fce si NeuroAiD es adecuado para su caso.<\/span><\/h3>\n<h4 style=\"text-align: left;\"><span style=\"color: #ffffff;\">Para enviar sus preguntas a nuestro equipo de Atenci\u00f3n al paciente, haga clic en el cuadro siguiente. En caso de duda, consulte siempre a su m\u00e9dico.<\/span><\/h4>\n[\/vc_column_text][nectar_btn size=\u00bblarge\u00bb button_style=\u00bbregular\u00bb button_color_2=\u00bbAccent-Color\u00bb color_override=\u00bb#f57b20&#8243; icon_family=\u00bbnone\u00bb text=\u00bbHAGA SUS PREGUNTAS\u00bb margin_top=\u00bb30&#8243; margin_bottom=\u00bb30&#8243; css_animation=\u00bbbounceIn\u00bb url=\u00bbhttps:\/\/neuroaid.com\/es\/contacto\/\u00bb][\/vc_column][vc_column column_padding=\u00bbno-extra-padding\u00bb column_padding_tablet=\u00bbinherit\u00bb column_padding_phone=\u00bbinherit\u00bb column_padding_position=\u00bball\u00bb top_margin=\u00bb30&#8243; column_element_direction_desktop=\u00bbdefault\u00bb column_element_spacing=\u00bbdefault\u00bb desktop_text_alignment=\u00bbdefault\u00bb tablet_text_alignment=\u00bbdefault\u00bb phone_text_alignment=\u00bbdefault\u00bb background_color_opacity=\u00bb1&#8243; background_hover_color_opacity=\u00bb1&#8243; column_backdrop_filter=\u00bbnone\u00bb column_shadow=\u00bbnone\u00bb column_border_radius=\u00bbnone\u00bb column_link_target=\u00bb_self\u00bb column_position=\u00bbdefault\u00bb gradient_direction=\u00bbleft_to_right\u00bb overlay_strength=\u00bb0.3&#8243; width=\u00bb1\/3&#8243; tablet_width_inherit=\u00bbsmall_desktop\u00bb animation_type=\u00bbdefault\u00bb bg_image_animation=\u00bbnone\u00bb border_type=\u00bbsimple\u00bb column_border_width=\u00bbnone\u00bb column_border_style=\u00bbsolid\u00bb column_padding_type=\u00bbdefault\u00bb gradient_type=\u00bbdefault\u00bb][image_with_animation image_url=\u00bb55&#8243; image_size=\u00bbfull\u00bb max_width=\u00bb100%\u00bb max_width_mobile=\u00bbdefault\u00bb animation_type=\u00bbentrance\u00bb animation=\u00bbFade In\u00bb animation_easing=\u00bbdefault\u00bb animation_movement_type=\u00bbtransform_y\u00bb hover_animation=\u00bbnone\u00bb alignment=\u00bbcenter\u00bb border_radius=\u00bbnone\u00bb box_shadow=\u00bbnone\u00bb image_loading=\u00bbdefault\u00bb margin_top=\u00bb30&#8243; margin_top_tablet=\u00bb30%\u00bb margin_top_phone=\u00bb2%\u00bb][\/vc_column][\/vc_row][vc_row type=\u00bbfull_width_content\u00bb full_screen_row_position=\u00bbmiddle\u00bb column_margin=\u00bbdefault\u00bb column_direction=\u00bbdefault\u00bb column_direction_tablet=\u00bbdefault\u00bb column_direction_phone=\u00bbdefault\u00bb bg_color=\u00bb#19388a\u00bb scene_position=\u00bbcenter\u00bb bottom_padding=\u00bb2%\u00bb bottom_padding_tablet=\u00bb2%\u00bb top_padding_phone=\u00bb0&#8243; bottom_padding_phone=\u00bb10%\u00bb top_margin=\u00bb0&#8243; bottom_margin=\u00bb0&#8243; top_margin_phone=\u00bb-1&#8243; text_color=\u00bbdark\u00bb text_align=\u00bbcenter\u00bb row_border_radius=\u00bbnone\u00bb row_border_radius_applies=\u00bbbg\u00bb overflow=\u00bbvisible\u00bb overlay_strength=\u00bb0.3&#8243; gradient_direction=\u00bbleft_to_right\u00bb shape_divider_color=\u00bb#ffffff\u00bb shape_divider_position=\u00bbtop\u00bb shape_divider_height=\u00bb80&#8243; bg_image_animation=\u00bbnone\u00bb shape_type=\u00bbcurve\u00bb gradient_type=\u00bbdefault\u00bb][vc_column column_padding=\u00bbno-extra-padding\u00bb column_padding_tablet=\u00bbinherit\u00bb column_padding_phone=\u00bbinherit\u00bb column_padding_position=\u00bball\u00bb bottom_margin=\u00bb0&#8243; left_margin_tablet=\u00bb0&#8243; right_margin_tablet=\u00bb0&#8243; column_element_direction_desktop=\u00bbdefault\u00bb column_element_spacing=\u00bbdefault\u00bb centered_text=\u00bbtrue\u00bb desktop_text_alignment=\u00bbdefault\u00bb tablet_text_alignment=\u00bbdefault\u00bb phone_text_alignment=\u00bbdefault\u00bb background_color=\u00bb#19388a\u00bb background_color_opacity=\u00bb1&#8243; background_hover_color_opacity=\u00bb1&#8243; column_backdrop_filter=\u00bbnone\u00bb column_shadow=\u00bbnone\u00bb column_border_radius=\u00bbnone\u00bb column_link_target=\u00bb_self\u00bb column_position=\u00bbdefault\u00bb gradient_direction=\u00bbleft_to_right\u00bb overlay_strength=\u00bb0.3&#8243; width=\u00bb1\/1&#8243; tablet_width_inherit=\u00bbsmall_desktop\u00bb animation_type=\u00bbdefault\u00bb bg_image_animation=\u00bbnone\u00bb border_type=\u00bbsimple\u00bb column_border_width=\u00bbnone\u00bb column_border_style=\u00bbsolid\u00bb column_padding_type=\u00bbdefault\u00bb gradient_type=\u00bbdefault\u00bb][page_submenu alignment=\u00bbcenter\u00bb bg_color=\u00bb#19388a\u00bb link_color=\u00bb#ffffff\u00bb][page_link link_url=\u00bbhttps:\/\/neuroaid.com\/es\/\u00bb title=\u00bbInicio\u00bb id=\u00bb1697076265075-0&#8243; tab_id=\u00bb1697076265075-8&#8243;][vc_column_text][\/vc_column_text][\/page_link][page_link link_url=\u00bbhttps:\/\/neuroaid.com\/es\/acerca-de-neuroaid\/\u00bb title=\u00bbAcerca de NeuroAiD\u00bb id=\u00bb1697076265098-5&#8243; tab_id=\u00bb1697076265098-8&#8243;][vc_column_text][\/vc_column_text][\/page_link][page_link title=\u00bbAcerca de Moleac\u00bb id=\u00bb1697076265109-10&#8243; tab_id=\u00bb1697076265109-6&#8243; link_url=\u00bbhttp:\/\/www.moleac.com\/\u00bb][\/page_link][page_link title=\u00bbDistribuidores\u00bb id=\u00bb1697076265122-10&#8243; link_url=\u00bbhttps:\/\/neuroaid.com\/es\/distribuidores\/\u00bb tab_id=\u00bb1697076265122-9&#8243;][\/page_link][page_link title=\u00bbCl\u00e1usulas y condiciones\u00bb id=\u00bb1697076265132-6&#8243; link_url=\u00bbhttps:\/\/neuroaid.com\/es\/clausulas-y-condiciones\/\u00bb tab_id=\u00bb1697076265132-4&#8243;][\/page_link][page_link title=\u00bbPol\u00edtica de privacidad\u00bb id=\u00bb1697076265142-4&#8243; link_url=\u00bbhttps:\/\/neuroaid.com\/es\/politica-de-privacidad\/\u00bb tab_id=\u00bb1697076265142-6&#8243;][\/page_link][page_link title=\u00bbPreguntas m\u00e1s frecuentes\u00bb id=\u00bb1697076265152-5&#8243; link_url=\u00bbhttps:\/\/neuroaid.com\/es\/preguntas-frecuentes\/\u00bb tab_id=\u00bb1697076265153-4&#8243;][\/page_link][\/page_submenu][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>[vc_row type=\u00bbfull_width_background\u00bb full_screen_row_position=\u00bbmiddle\u00bb column_margin=\u00bbdefault\u00bb column_direction=\u00bbdefault\u00bb column_direction_tablet=\u00bbdefault\u00bb column_direction_phone=\u00bbdefault\u00bb bg_color=\u00bb#ffffff\u00bb scene_position=\u00bbcenter\u00bb top_padding=\u00bb0&#8243;&#8230;<\/p>\n","protected":false},"author":8,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"class_list":["post-3331","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/neuroaid.com\/es\/wp-json\/wp\/v2\/pages\/3331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neuroaid.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/neuroaid.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/neuroaid.com\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/neuroaid.com\/es\/wp-json\/wp\/v2\/comments?post=3331"}],"version-history":[{"count":33,"href":"https:\/\/neuroaid.com\/es\/wp-json\/wp\/v2\/pages\/3331\/revisions"}],"predecessor-version":[{"id":256736,"href":"https:\/\/neuroaid.com\/es\/wp-json\/wp\/v2\/pages\/3331\/revisions\/256736"}],"wp:attachment":[{"href":"https:\/\/neuroaid.com\/es\/wp-json\/wp\/v2\/media?parent=3331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}